WO2021246413A1 - 抗igf-1受容体ヒト化抗体 - Google Patents
抗igf-1受容体ヒト化抗体 Download PDFInfo
- Publication number
- WO2021246413A1 WO2021246413A1 PCT/JP2021/020890 JP2021020890W WO2021246413A1 WO 2021246413 A1 WO2021246413 A1 WO 2021246413A1 JP 2021020890 W JP2021020890 W JP 2021020890W WO 2021246413 A1 WO2021246413 A1 WO 2021246413A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- igf
- seq
- receptor
- antibody
- Prior art date
Links
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 103
- 241000282414 Homo sapiens Species 0.000 claims abstract description 77
- 239000012634 fragment Substances 0.000 claims abstract description 68
- 238000006467 substitution reaction Methods 0.000 claims abstract description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 215
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims description 154
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims description 143
- 210000004027 cell Anatomy 0.000 claims description 135
- 108020003175 receptors Proteins 0.000 claims description 130
- 102000005962 receptors Human genes 0.000 claims description 129
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 125
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 121
- 230000000694 effects Effects 0.000 claims description 112
- 238000000034 method Methods 0.000 claims description 108
- 210000004369 blood Anatomy 0.000 claims description 89
- 239000008280 blood Substances 0.000 claims description 89
- 210000003205 muscle Anatomy 0.000 claims description 77
- 230000027455 binding Effects 0.000 claims description 71
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 66
- 239000008103 glucose Substances 0.000 claims description 65
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 62
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 57
- 241001465754 Metazoa Species 0.000 claims description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 201000010099 disease Diseases 0.000 claims description 48
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 230000004663 cell proliferation Effects 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 230000004913 activation Effects 0.000 claims description 33
- 230000001939 inductive effect Effects 0.000 claims description 30
- 230000009471 action Effects 0.000 claims description 29
- 230000035755 proliferation Effects 0.000 claims description 29
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 24
- 208000024891 symptom Diseases 0.000 claims description 24
- 239000003446 ligand Substances 0.000 claims description 23
- 208000020221 Short stature Diseases 0.000 claims description 20
- 102000044162 human IGF1 Human genes 0.000 claims description 20
- 210000003098 myoblast Anatomy 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 19
- 102000018997 Growth Hormone Human genes 0.000 claims description 17
- 108010051696 Growth Hormone Proteins 0.000 claims description 17
- 239000000122 growth hormone Substances 0.000 claims description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- 230000004190 glucose uptake Effects 0.000 claims description 14
- 201000000585 muscular atrophy Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000003213 activating effect Effects 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 9
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 210000004349 growth plate Anatomy 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 208000001076 sarcopenia Diseases 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 210000000845 cartilage Anatomy 0.000 claims description 7
- 238000010494 dissociation reaction Methods 0.000 claims description 7
- 230000005593 dissociations Effects 0.000 claims description 7
- 230000001817 pituitary effect Effects 0.000 claims description 7
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010028372 Muscular weakness Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 4
- 208000008383 Wilms tumor Diseases 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000036473 myasthenia Effects 0.000 claims description 4
- 201000008026 nephroblastoma Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000003154 papilloma Diseases 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 210000002460 smooth muscle Anatomy 0.000 claims description 4
- 210000004500 stellate cell Anatomy 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 206010042863 synovial sarcoma Diseases 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 208000003807 Graves Disease Diseases 0.000 claims description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims description 3
- 230000009702 cancer cell proliferation Effects 0.000 claims description 3
- 239000013599 cloning vector Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 3
- 230000002861 ventricular Effects 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 208000007054 Medullary Carcinoma Diseases 0.000 claims description 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 208000037804 stenosis Diseases 0.000 claims description 2
- 210000003273 vestibular nerve Anatomy 0.000 claims description 2
- 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 claims 1
- 102100033269 Cyclin-dependent kinase inhibitor 1C Human genes 0.000 claims 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 85
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 61
- 235000001014 amino acid Nutrition 0.000 description 54
- 239000003814 drug Substances 0.000 description 51
- 229940079593 drug Drugs 0.000 description 40
- 229940024606 amino acid Drugs 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 39
- 238000005259 measurement Methods 0.000 description 34
- 230000001965 increasing effect Effects 0.000 description 33
- 239000000126 substance Substances 0.000 description 27
- 239000000427 antigen Substances 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 241000700198 Cavia Species 0.000 description 22
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 241000282412 Homo Species 0.000 description 20
- 230000005847 immunogenicity Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 210000000056 organ Anatomy 0.000 description 18
- 241000282567 Macaca fascicularis Species 0.000 description 17
- 241000700199 Cavia porcellus Species 0.000 description 16
- 239000000556 agonist Substances 0.000 description 16
- 230000003834 intracellular effect Effects 0.000 description 16
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 14
- 210000004748 cultured cell Anatomy 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 229940044601 receptor agonist Drugs 0.000 description 14
- 239000000018 receptor agonist Substances 0.000 description 14
- 241000282693 Cercopithecidae Species 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 239000002464 receptor antagonist Substances 0.000 description 13
- 229940044551 receptor antagonist Drugs 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 102000003746 Insulin Receptor Human genes 0.000 description 12
- 108010001127 Insulin Receptor Proteins 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 230000006240 deamidation Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- -1 polyoxyethylene Polymers 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 235000004279 alanine Nutrition 0.000 description 9
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 9
- 229910002091 carbon monoxide Inorganic materials 0.000 description 9
- 208000019425 cirrhosis of liver Diseases 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 235000009582 asparagine Nutrition 0.000 description 8
- 229960001230 asparagine Drugs 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 108010000594 mecasermin Proteins 0.000 description 8
- 210000002027 skeletal muscle Anatomy 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000006820 DNA synthesis Effects 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 229960001311 mecasermin Drugs 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- 229940125644 antibody drug Drugs 0.000 description 6
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 206010062767 Hypophysitis Diseases 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 208000030941 fetal growth restriction Diseases 0.000 description 5
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 210000003635 pituitary gland Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 4
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 4
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 235000013861 fat-free Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 238000000126 in silico method Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 3
- 206010070531 Foetal growth restriction Diseases 0.000 description 3
- 208000001204 Hashimoto Disease Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 3
- 239000000488 activin Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000012054 celltiter-glo Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 230000002608 insulinlike Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012557 regeneration buffer Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000004683 skeletal myoblast Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000010421 standard material Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000022540 Consciousness disease Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010000178 IGF-I-IGFBP-3 complex Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 101000935589 Mus musculus Flavin reductase (NADPH) Proteins 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 201000011032 Werner Syndrome Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010016165 failure to thrive Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000009593 intrauterine fetal growth Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229960004882 medetomidine hydrochloride Drugs 0.000 description 2
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 230000009753 muscle formation Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000002165 resonance energy transfer Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229950010259 teprotumumab Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000001720 vestibular Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150107888 AKT2 gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 101100244725 Caenorhabditis elegans pef-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 101150034979 DRB3 gene Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 208000008924 Femoral Fractures Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000000393 Ghrelin Receptors Human genes 0.000 description 1
- 108010016122 Ghrelin Receptors Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 101710099093 Growth hormone receptor Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 108091008551 RET receptors Proteins 0.000 description 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 206010062282 Silver-Russell syndrome Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229920000800 acrylic rubber Polymers 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 108010052640 anamorelin Proteins 0.000 description 1
- VQPFSIRUEPQQPP-MXBOTTGLSA-N anamorelin Chemical compound C([C@@]1(C(=O)N(C)N(C)C)CN(CCC1)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 VQPFSIRUEPQQPP-MXBOTTGLSA-N 0.000 description 1
- 229950005896 anamorelin Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003607 granisetron hydrochloride Drugs 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- QYZRTBKYBJRGJB-UHFFFAOYSA-N hydron;1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3CC4CCCC(C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229940023383 increlex Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012434 mixed-mode chromatography Methods 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 108010088102 mouse insulin-like growth factor-1 Proteins 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- MUZQPDBAOYKNLO-RKXJKUSZSA-N oxycodone hydrochloride Chemical compound [H+].[Cl-].O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C MUZQPDBAOYKNLO-RKXJKUSZSA-N 0.000 description 1
- 229940118537 p53 inhibitor Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108010077161 rat insulin-like growth factor-1 Proteins 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 108091008601 sVEGFR Proteins 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000013707 sensory perception of sound Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000013706 tumor of meninges Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention relates to an anti-IGF-1 receptor humanized antibody. Specifically, it relates to an anti-IGF-1 receptor humanized antibody that specifically binds to the IGF-1 receptor.
- IGF-1 is an insulin-like growth factor that is secreted mainly from the liver and acts on the IGF-1 receptor through activation of GH receptors by growth hormone (GH) secreted from the pituitary gland. Therefore, various physiological functions are expressed in various organs. From this, IGF-1 is expected to be treated for various diseases. Since IGF-1 has a high homology of about 40% as compared with the amino acid sequence of proinsulin, it may also bind to the insulin receptor and exert an insulin-like action. In addition, since the IGF-1 receptor has a high homology of about 60% compared to the amino acid sequence of the insulin receptor, both receptors also exert a physiological effect by forming a heterodimer. Demonstrate. Insulin is used therapeutically as a hypoglycemic agent because it exerts a strong hypoglycemic effect by acting on the insulin receptor.
- GH growth hormone
- IGF-1 receptor The IGF-1 receptor is composed of ⁇ and ⁇ chains and contains six extracellular domains, transmembrane domains, and intracellular domains of L1, CR, L2, Fn1, Fn2, and Fn3. It is a penetrating protein.
- the intracellular domain of the IGF-1 receptor has a tyrosine kinase.
- the extracellular domain is involved in the activation of intracellular tyrosine kinases associated with changes in the conformation of IGF-1 when it binds to the IGF-1 receptor.
- the IGF-1 receptor forms a homodimer complex (homotype), and when IGF-1 binds, it signals by activating the receptor kinase. It also forms a heterodimer complex (heterotype) with the insulin receptor, and when insulin or IGF-1 binds, it signals by activating the receptor kinase.
- IGF-1 Physiological action of IGF-1 IGF-1 has been clarified to have a growth promoting action such as height and weight gain, and an insulin-like metabolic action such as glucose metabolism promoting action and blood glucose lowering action.
- Mecasermin a human recombinant IGF-1, has been shown to improve symptoms of insulin receptor abnormalities such as hyperglycemia, hyperinsulinemia, acanthosis nigricans and hirsutism. It has also been found to improve growth failure in growth hormone-resistant short stature (Non-Patent Document 1).
- IGF-1 is a major factor in promoting growth (Non-Patent Document 2 and Non-Patent Document 3).
- mecasermin a human recombinant IGF-1
- IGF-1 is known to enhance the DNA synthesis ability of human chondrocytes.
- administration of IGF-1 increases the body weight of pituitary-excised rats and prolongs the length of the femoral bone.
- IGF-1 Muscle mass-increasing action of IGF-1
- the enhancement of cell proliferation activity mediated by IGF-1 requires continuous activation of the IGF-1 receptor. Muscle mass is increased in animals that overexpress the IGF-1 receptor.
- continuous administration of IGF-1 / IGFBP3 enhances grip strength in patients with proximal femoral fractures and improves their ability to stand up from a sitting position without assistance. It is known that the IGF-1 concentration in the muscles of aged humans and mice is lower than that of young mice, but in aged mice in which IGF-1 is forcibly expressed in a muscle tissue-specific manner, it is wild. Compared with the type mouse, the muscle mass was improved (Non-Patent Document 4).
- Anamorelin an agonist of the predecessor ghrelin receptor that increases muscle mass, increased lean body mass in a clinical trial of disuse muscular atrophy, Kakexia.
- Myostatin is a negative regulator of skeletal muscle formation that acts on activin receptor II (ActRII) and inhibits Akt / mTOR.
- ActRII activin receptor II
- the anti-myostatin antibody LY2495655 increases muscle mass in patients and the elderly who have undergone total hip arthroplasty.
- Vimaglumab an anti-ActRII antibody, also increases muscle mass in patients with neuromuscular disease.
- IGF-1 As an insulin-like action of IGF-1, a hypoglycemic action is known. IGF-1 enhances glucose uptake in rat muscle-derived cells. In addition, administration of IGF-1 lowers blood glucose levels in rats. It has been reported that the hypoglycemic effect of IGF-1 causes hypoglycemic symptoms as a clinical side effect. Furthermore, since IGF-1 causes hypoglycemic symptoms when administered to humans, it is necessary to administer appropriate doses in order from the lowest dose at the start of treatment and observe various clinical findings including blood glucose level after administration. It becomes.
- IGF-1 exerts a hypoglycemic effect through enhancement of Akt phosphorylation and the like. Active mutants of Akt enhance glucose uptake in 3T3-L1 cells. On the other hand, the blood glucose level of the mice lacking Akt2 increased. In addition, in rat muscle-derived cells, Akt inhibitors inhibit insulin-stimulated glucose uptake. Furthermore, IGF-1 is known to activate insulin receptors involved in hypoglycemic action. From these facts, it is considered that the hypoglycemic effect of IGF-1 involves excessive activation of Akt and activation of insulin receptor.
- IGF-1 Short half-life of IGF-1
- mecasermin a human recombinant IGF-1
- IGFBP3 The free form of IGF-1 exhibits bioactivity. Binding to IGFBP3 maintains the blood half-life of IGF-1 from about 10 hours to 16 hours.
- IPLEX which is a combination drug of IGF-1 and IGFBP3, has a half-life in blood of about 21 to 26 hours, which is longer than that of IGF-1, and is a drug that can be administered once a day.
- IPLEX has withdrawn from the market.
- PEGylated IGF-1 which has improved the dynamics of IGF-1, has also been attempted to be developed, but no drug has been used for treatment.
- IGF-1 acts on various organs and its physiological functions are diverse. For example, IGF-1 has been reported to have a neuroprotective effect on mitochondrial protection and antioxidant activity in the central nervous system through activation of the IGF-1 receptor. IGF-1 promotes the formation of neurites after injury. IGF-1 is also believed to be useful in the treatment of liver cirrhosis. Cirrhosis is a disease that progresses from liver disorder or chronic liver disease and is accompanied by liver fibrosis. In liver cirrhosis model animals, administration of IGF-1 suppressed liver fibrosis. Furthermore, IGF-1 is known to be involved in the development and function of the kidney. In renal mesangial cells, IGF-1 has a protective effect against oxidative stress and apoptosis due to glycotoxicity. IGF-1 is expected as a therapeutic agent for nephropathy.
- IGF-1 Diseases expected to be improved by administration of IGF-1 include sarcopenia, disused muscular atrophy, caquexia, short stature, laronosis, liver cirrhosis, liver fibrosis, aging, intrauterine fetal growth retardation (IUGR), Neurological disorders, stroke, spinal cord injury, cardiovascular protection, diabetes, insulin resistance, metabolic syndrome, nephropathy, osteoporosis, sarcopenia, wound healing, muscular tonic dystrophy, AIDS muscle atrophy, fat associated with HIV There are redistribution syndrome, burns, Crohn's disease, Werner's syndrome, X-chain complex immunodeficiency, hearing loss, neurological appetite and premature infant retinopathy. As described above, IGF-1 is expected as a therapeutic agent for various diseases due to its various physiological actions. However, the side effects of lowering blood glucose and multiple administrations with a short half-life are challenges for clinical use.
- Anti-IGF-1 receptor agonist antibody antibody preparations generally have a long half-life and show efficacy when administered once or twice a month.
- Anti-IGF-1 receptor agonist antibodies have been reported to have some receptor-activating effects in short-term treatment in vitro.
- antibody 3B7 and antibody 2D1 promoted DNA synthesis in recombinant IGF-1 receptor-expressing cells cultured for 5 hours in vitro (Non-Patent Document 5).
- anti-IGF-1 receptor antagonist antagonists 11A1, 11A4, 11A11, and 24-57 which have antiproliferative activity in cancer cell lines, are extremely weak in vitro but phosphorylate tyrosine of the IGF-1 receptor. Increased (Non-Patent Document 6).
- Non-Patent Document 7 antibodies 16-13, 17-69, 24-57, 24-60, and 24-31 have been shown to have an effect of enhancing cellular DNA synthesis and glucose uptake in a short period of time in vitro. These antibodies may have a hypoglycemic effect (Non-Patent Document 7).
- Non-Patent Documents 5 to 5 It cannot be an index of an agonist antibody having cell proliferation activity.
- Non-Patent Documents 5 to 8 Furthermore, there were no reports of antibodies showing agonist activity against the IGF-1 receptor in vivo. In addition, since IGF-1 exerts both hypoglycemic action and cell proliferation action, it is necessary to avoid the hypoglycemic action in order to administer the anti-IGF-1 receptor agonist antibody as a therapeutic agent to humans. However, there have been no reports of such anti-IGF-1 receptor agonist antibodies so far.
- the antibody has a large molecular weight and low tissue transferability, and the intracerebral transferability is about 0.1% and the muscle tissue transferability is about 2%. Therefore, in order to exert an action in a tissue having low transferability of the antibody, an antibody showing sufficient pharmacological activity in an extremely low concentration range (pM order) is required.
- pM order pharmacological activity in an extremely low concentration range
- Anti-IGF-1 receptor monoclonal mouse antibody We have succeeded in producing IGF11-16. Furthermore, it has been confirmed that the obtained monoclonal mouse antibody induces a muscle mass increasing action and a growth plate stretching action in vivo without causing hypoglycemic symptoms (Patent Document 1).
- Anti-IGF-1 receptor antagonist antibody An antibody that binds to the IGF-1 receptor can be applied to the treatment of malignant tumors, etc. by utilizing the antagonistic action that inhibits the binding between IGF-1 and the IGF-1 receptor. Attempted.
- the existing anti-IGF-1 receptor antagonist antibody not only has many side effects such as hyperglycemia in monotherapy (Non-Patent Document 9), but also increases the incidence of hyperglycemia when used in combination with other anticancer agents. (Non-Patent Document 10), its application to treatment is considered to be limited.
- Teprotumumab has been approved for the indication of ophthalmopathy in hyperthyroidism (Non-Patent Document 11).
- Musaro, A., et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle, Nature Genetics, 2001, Vol.27, No.2, pp.195-200 Xiong, L., et al., Growth-stimulatory monoclonal antibody antibodies against human insulin-like growth factor I receptor. Proc Natl Acad Sci U S A, 1992. 89 (12): p. 5356-60. Runnels, H.A., et al., Human monoclonal antibody to the insulin-like growth factor 1 receptor inhibitor receptor activation and tumor growth in precursor clinical studies. Adv Ther, 2010. 27 (7): p.
- Soos, MA, et al. A panel of monoclonal antibody for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem, 1992. 267 (18): p -63.
- Kato, H., et al. Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor.
- the present invention is an anti-IGF-1 receptor humanized antibody or an anti-IGF-1 receptor humanized antibody thereof having a specificity equal to or higher than that of the previously reported anti-IGF-1 receptor mouse antibody IGF11-16 (Patent Document 1) and binding affinity or activity.
- Patent Document 1 One of the purposes thereof is to provide a fragment, a derivative thereof, or a method for producing them.
- the specific object of the present invention is not limited to these, but is, for example, specificity equal to or higher than that of the previously reported anti-IGF-1 receptor mouse antibody IGF11-16 (Patent Document 1), and binding.
- Patent Document 1 In order to obtain humanized antibodies having affinity or activity, (1) provision of amino acids essential for the design of human framework, (2) CDR sequence which is an antigen binding site (identified by the Kabat method in the present invention). Examples thereof include provision of amino acid sites essential for maintaining activity, (3) provision of amino acid substitutions for reducing immunogenicity, and (4) provision of amino acid substitutions for avoiding the risk of deamidation.
- an anti-IGF-1 receptor humanized antibody capable of increasing muscle mass via the human IGF-1 receptor without inducing hypoglycemic symptoms.
- an anti-IGF-1 receptor that can be administered to a human for the purpose of ameliorating or treating a pathological condition or disease associated with an IGF-1 receptor signal, such as sarcopenia, disused muscular atrophy, or Kakexia.
- Humanized antibodies can be obtained.
- the present invention relates to the following.
- CDRs heavy chain and light chain complementarity determining regions
- FR heavy chain and light chain framework regions
- CDR-1 CDR-H1
- CDR-2 CDR-H2
- amino acid sequence of the heavy chain variable region amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 5
- amino acid sequence of SEQ ID NO: 7 amino acid sequence in which any one or two amino acid residues of SEQ ID NO: 7 are substituted.
- CDR-1 CDR-L1 sequence of the light chain variable region
- amino acid sequence of SEQ ID NO: 9 amino acid sequence in which any one or two amino acid residues of SEQ ID NO: 9 are substituted
- CDR-2 CDR-L2 sequence of the light chain variable region
- amino acid sequence of SEQ ID NO: 11 or the amino acid sequence in which any one of the amino acid residues of SEQ ID NO: 11 is substituted.
- a term comprising, as the CDR-3 (CDR-L3) sequence of the light chain variable region, the amino acid sequence of SEQ ID NO: 13 or the amino acid sequence in which any one or two amino acid residues of SEQ ID NO: 13 are substituted.
- the anti-IGF-1 receptor humanized antibody or fragment thereof according to [1] or [2], or a derivative thereof.
- CDR-2 (CDR-H2) sequence of the heavy chain variable region an amino acid sequence having 82% or more homology with SEQ ID NO: 3 or SEQ ID NO: 5
- CDR-3 (CDR-H3) sequence of the heavy chain variable region an amino acid sequence having 75% or more homology with SEQ ID NO: 7
- As the CDR-1 (CDR-L1) sequence of the light chain variable region an amino acid sequence having 81% or more homology with SEQ ID NO: 9
- CDR-2 (CDR-L2) sequence of the light chain variable region an amino acid sequence having 85% or more homology with SEQ ID NO: 11.
- CDR-1 (CDR-H1) sequence of the heavy chain variable region the amino acid sequence in which the Trp at position 3 of SEQ ID NO: 1 is maintained or replaced with a similar amino acid residue is the 3
- An amino acid sequence in which any one amino acid residue other than the amino acid residue at the position is substituted or has 80% or more homology with SEQ ID NO: 1.
- CDR-2 CDR-H2 sequence of the heavy chain variable region
- CDR-H2 CDR-2 sequence of the heavy chain variable region
- the amino acid residues at any one, two, or three positions other than the amino acid residues at the 1st, 3rd, and 6th positions are substituted, or the amino acid residue is 82% or more homologous with SEQ ID NO: 3.
- Amino acid sequence having sex or An amino acid sequence in which Glu at position 1 and Asn at position 3 of SEQ ID NO: 5 are maintained or replaced with similar amino acid residues, and Ser at position 6 is maintained or replaced with Asn or Gln, respectively.
- the amino acid residues at any one, two, or three positions other than the amino acid residues at the 1, 3, and 6 positions are substituted, or the amino acid residue is 82% or more homologous with SEQ ID NO: 5.
- Amino acid sequence with sex As the CDR-3 (CDR-H3) sequence of the heavy chain variable region, the amino acid sequence in which Arg at the 4-position of SEQ ID NO: 7 is maintained or substituted with a similar amino acid residue is the amino acid at the 4-position.
- the amino acid sequence in which the Trp at position 9 of SEQ ID NO: 9 is maintained or substituted with a similar amino acid residue as the CDR-1 (CDR-L1) sequence of the light chain variable region is the amino acid at position 9.
- CDR-3 (CDR-L3) sequence of the light chain variable region an amino acid residue at any one or two sites of SEQ ID NO: 13 is substituted, or an amino acid having 77% or more homology with SEQ ID NO: 13
- the heavy chain variable region one or several places in the amino acid sequence of SEQ ID NO: 43, 47, 49, 53, 55, or 59, or the amino acid sequence of SEQ ID NO: 43, 47, 49, 53, 55, or 59.
- the anti-IGF-1 receptor humanized antibody according to any one of Items [1] to [6], which comprises an amino acid sequence having 90% or more homology with SEQ ID NO: 65, 67, or 69. Or a fragment thereof, or a derivative thereof. [8] Any one of items [1] to [7], wherein the constant region of the heavy chain and / or the light chain includes the constant region of the heavy chain and / or the light chain of any class of human immunoglobulin.
- the anti-IGF-1 receptor humanized antibody or fragment thereof according to the above, or a derivative thereof.
- KD equilibrium dissociation constant
- the anti-IGF-1 receptor according to any one of Items [1] to [15], which can induce growth plate cartilage elongation action without inducing hypoglycemic symptoms in a pituitary excision model animal. Humanized antibodies or fragments thereof, or derivatives thereof. [17] Any of the items [1] to [16], which does not lower the blood glucose level of the vertebrate when administered to the vertebrate at a dose that induces an increase in muscle mass and / or length of the vertebrate.
- the anti-IGF-1 receptor humanized antibody or fragment thereof according to paragraph 1, or a derivative thereof.
- the humanized antibody or fragment thereof according to any one of the above, or a derivative thereof.
- a pharmaceutical composition comprising the recombinant cell according to item [27] as an active ingredient.
- the pharmaceutical composition according to item [29] which is used for the treatment of amyotrophic disease or short stature.
- the pharmaceutical composition according to item [30] wherein the amyotrophic disease is disuse muscular atrophy, sarcopenia, or cachexia.
- the pharmaceutical composition according to item [28], wherein the short stature is Laron-type short stature or growth hormone-resistant short stature.
- the pharmaceutical composition according to item [29] which is used for treating a disease associated with an IGF-1 receptor.
- IGF-I receptor-related diseases include liver cancer, neuroblastoma, rhabdomyomyoma, osteosarcoma, pediatric cancer, apical giant disease, ovarian cancer, pancreatic cancer, and benign prostate enlargement.
- Antibodies of the invention or fragments thereof, or derivatives thereof, can be used for the treatment or prevention of diseases acting via the human IGF-1 receptor by binding to the human IGF-1 receptor, anti-IGF-.
- One receptor humanized antibody can be obtained.
- 1A to 1F are graphs showing the human myoblast proliferation activity of various humanized antibodies of the present invention in comparison with the mouse parent antibody IGF11-16. Same as above. Same as above. Same as above. Same as above. Same as above. Same as above. Same as above. Same as above. Same as above. Same as above. Same as above.
- FIG. 2 shows the reactivity of the humanized antibodies hIGF13_PS and hIGF25_PS of the present invention against IGF-1R of each animal species, measured by ELISA using HEK293T cells expressing IGF-1R of each animal species, in a human mouse chimera. It is a graph which shows the comparison with the antibody IGF11-16.
- FIG. 3A is a graph showing changes in blood glucose level when the humanized antibody hIGF13_PS of the present invention is administered to a guinea pig.
- FIG. 3B is a graph showing changes in blood glucose level when the humanized antibody hIGF25_PS of the present invention is administered to a guinea pig.
- FIG. 4 is a graph showing changes in blood concentration when the humanized antibodies hIGF13_PS and hIGF25_PS of the present invention are administered to guinea pigs in comparison with those when the mouse parent antibody IGF11-16 is administered.
- FIG. 5 shows changes in the mass of the extensor digitorum longus muscle after 2 weeks when the humanized antibody hIGF13_PS of the present invention was intravenously administered to a normal guinea pig by continuous subcutaneous administration of IGF-1 and the mouse parent antibody IGF11-16. It is a graph which shows the comparison with the single intravenous administration of.
- FIG. 6 shows changes in the epiphyseal line thickness of the proximal tibia after 2 weeks when the humanized antibody hIGF13_PS of the present invention was intravenously administered to a pituitary gland excised guinea pig by continuous subcutaneous administration of IGF-1. It is a graph which shows the comparison with the subcutaneous continuous administration of the GH preparation.
- FIG. 7 is a graph showing changes in blood glucose level when the humanized antibody hIGF13_PS of the present invention is administered to cynomolgus monkeys in comparison with the time of administration of IGF-1.
- FIG. 8 is a graph showing changes in blood concentration when the humanized antibody hIGF13_PS of the present invention is administered to cynomolgus monkeys.
- FIG. 9 is a graph showing the concentration-dependent effect of the mouse parent antibody IGF11-16 on HepG2 cell proliferation.
- M indicating the concentration is a unit synonymous with "mol / L” indicating the molar concentration.
- the present invention is an anti-IGF-1 receptor humanized antibody that specifically binds to the IGF-1 receptor.
- the antibody of the present invention has an action of increasing muscle mass via the human IGF-1 receptor without inducing hypoglycemic symptoms. This makes it possible to ameliorate or treat conditions or diseases involving IGF-1 receptor signals such as sarcopenia, disuse muscular atrophy, and Kakexia. Further, the antibody of the present invention is a humanized antibody that ensures low immunogenicity and physical stability.
- IGF insulin-like Growth Factor
- IGF-1 and IGF-2 are present. IGF-1 and IGF-2 bind to the IGF-1 receptor (Insulin-like Growth Factor-I Receptor) described later, and signal intracellular cell division and metabolism. It is an in vivo ligand that has an agonistic activity to enter. IGF-1 and IGF-2 are also known to weakly and cross-link to the insulin receptor (INSR), which is structurally similar to the IGF-1 receptor. In the present specification, IGF-1 whose physiological function is better known is mainly dealt with, but when examining the action or disease through the binding between the IGF-1 receptor and the ligand, IGF is used. The effects of both -1 and IGF-2 may be included.
- IGF-1 and IGF-2 may be included.
- IGF-1 is also called somatomedin C and is a hormone of a single polypeptide consisting of 70 amino acids.
- the sequence of human IGF-1 can be obtained by referring to NCBI Reference Sequence No .: NP_000609, or EMBL-EBI UniProt KB-Axon No. P05019 and the like.
- the amino acid sequence of mature human IGF-1 is shown in SEQ ID NO: 83, and an example of the corresponding nucleic acid base sequence is shown in SEQ ID NO: 84.
- This 70-amino acid sequence is conserved in many species. In the present invention, when only "IGF-1" is described, it means an IGF-1 protein having hormonal activity unless otherwise specified.
- IGF-1 is produced in various cells in the living body including liver cells, and is also present in blood and other body fluids. Therefore, the natural form of IGF-1 can be obtained by purifying from the body fluid of an animal or a culture obtained by culturing primary cultured cells or cell lines separated from the animal. In addition, since IGF-1 is induced to be produced in cells by growth hormone, body fluids of animals to which growth hormone was administered, primary cultured cells separated from animals, established cells, etc. were cultured in the presence of growth hormone. It can also be obtained by purifying IGF-1 from the culture.
- a nucleic acid molecule encoding the amino acid sequence of IGF-1 was incorporated into an expression vector and introduced into a host of prokaryotes such as Escherichia coli and eukaryotic cells such as yeast, insect cells or cultured cells derived from mammals. It is also possible to produce IGF-1 using recombinant cells, transgenic animals into which the IGF-1 gene has been introduced, transgenic plants, and the like.
- human IGF-1 is a research reagent (Enzo Life Sciences, catalog: ADI-908-059-0100; Abnova, catalog: P3452, etc.), pharmaceuticals (Somazon (registered trademark) , mecasermin, INCRELEX (registered trademark), etc.).
- IGF-1 used is 1 international unit / microgram of activity on the IGF-1 standard material of the NIBSC code: 91/554 of the World Health Organization's National Institute for Biological Standards and Control (NIBSC).
- the specific activity can be evaluated by comparing with.
- IGF-1 in the present invention shall be treated as having a specific activity equivalent to that of IGF-1 of the NIBSC code: 91/554.
- IGF-1 receptor refers to an insulin-like Growth Factor-I Receptor.
- IGF-1 receptor means an IGF-1 receptor protein unless otherwise specified.
- the IGF-1 receptor is a protein with a structure in which two subunits consisting of an ⁇ chain and a ⁇ chain are associated.
- SEQ ID NO: 71 the portion of the amino acid sequence consisting of the amino acid sequences at positions 31 to 735 corresponds to the ⁇ chain, and the ⁇ chain is the sequence after position 740. Corresponds to.
- the ⁇ chain of the IGF-1 receptor has a binding portion of IGF-1, and the ⁇ chain has a transmembrane structure and functions to transmit a signal into the cell.
- the ⁇ chain of the IGF-1 receptor is divided into L1, CR, L2, FnIII-1 and FnIII-2a / ID / FnIII-2b domains.
- the portion from position 31 to 179 is the L1 domain
- the portion from position 180 to position 328 is the CR domain
- the portion from position 329 to position 491 is the L2 domain.
- the portion from position 492 to position 607 corresponds to the FnIII-1 domain, and the portion from position 608 to position 735 corresponds to the FnIII-2a / ID / FnIII-2b domain.
- the amino acid sequence of the human IGF-1 receptor can be referred to from UniProtKB-Axon No. P08069 of EMBL-EBI, etc., and is also shown in SEQ ID NO: 71 of the sequence listing.
- the IGF-1 receptor is expressed in a wide range of tissues and cells in the living body, and is stimulated by IGF-1 such as induction of cell proliferation and activation of intracellular signals.
- myoblasts can use the IGF-1 receptor-mediated action of IGF-1 for evaluation using the cell proliferation activity as an index. This makes myoblasts useful for analyzing the action of antibodies that bind to the IGF-1 receptor.
- a recombinant in which a nucleic acid molecule encoding the amino acid sequence of the IGF-1 receptor of humans and other vertebrates is incorporated into an expression vector and introduced into a host of eukaryotic cells such as insect cells or cultured cells derived from mammals.
- the IGF-1 receptor-expressing cells can be used for analysis of antibody binding and examination of intracellular signal transduction.
- mouse parent antibody IGF11-16 The mouse parent antibody IGF11-16 is disclosed in Patent Document 1.
- the amino acid sequence of CDR-H1 of IGF11-16 is SEQ ID NO: 85
- the nucleic acid sequence of CDR-H2 is SEQ ID NO: 86
- the amino acid sequence of CDR-H3 is SEQ ID NO: 87
- the amino acid sequence of CDR-L1 is SEQ ID NO: 88
- CDR- CDR-.
- the amino acid sequence of L2 is SEQ ID NO: 89
- the amino acid sequence of CDR-L3 is SEQ ID NO: 90
- the amino acid sequence of the heavy chain variable region is SEQ ID NO: 39 (an example of the corresponding nucleic acid base sequence is SEQ ID NO: 40), and the light chain variable region.
- the amino acid sequence is shown in SEQ ID NO: 41 (an example of the corresponding nucleic acid base sequence is SEQ ID NO: 42).
- the full-length amino acid sequence of the light chain of IGF11-16 is SEQ ID NO: 91 (an example of the corresponding nucleobase sequence, SEQ ID NO: 92), and the full-length amino acid sequence of the heavy chain is SEQ ID NO: 93 (an example of the corresponding nucleobase sequence).
- All antibodies comprising the expression IGF11-16 mean this mouse parent antibody IGF11-16.
- an “antibody” is a glycoprotein containing at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds.
- Each heavy chain contains a heavy chain variable region (abbreviated as VH) and a heavy chain constant region, and the heavy chain constant region contains three domains, CH1, CH2 and CH3.
- Each light chain contains a light chain variable region (abbreviated as VL) and a light chain constant region.
- the light chain constant region contains one domain, CL.
- VHs and VLs are further referred to as framework regions (FRs), four more conserved regions (FR-1 (FR1), FR-2 (FR2), FR-3 (FR3), FR-4. (FR4)) and three hypervariable regions (CDR-1 (CDR1), CDR-2 (CDR2), CDR-3 (CDR3)) called complementarity determining regions (CDRs). ..
- VH is from the amino terminus to the carboxy terminus, FR-1 (FR-H1), CDR-1 (CDR-H1), FR-2 (FR-H2), CDR-2 (CDR-H2), FR-3 ( It contains 3 CDRs and 4 FRs arranged in the order of FR-H3), CDR-3 (CDR-H3), FR-4 (FR-H4).
- VL is from the amino terminus to the carboxy terminus, FR-1 (FR-L1), CDR-1 (CDR-L1), FR-2 (FR-L2), CDR-2 (CDR-L2), FR-3 ( It contains 3 CDRs and 4 FRs arranged in the order of FR-L3), CDR-3 (CDR-L3), FR-4 (FR-L4).
- the variable regions of the heavy and light chains contain binding domains that interact with the antigen.
- the antibody of the present invention may be a fragment and / or a derivative of the antibody.
- the antibody fragment include F (ab') 2 , Fab, Fv and the like.
- the antibody derivative an antibody in which an amino acid mutation is artificially introduced into the constant region portion, an antibody in which the composition of the constant region domain is modified, an antibody having two or more Fc per molecule, a heavy chain only or light chain Chain-only antibodies, sugar chain-modified antibodies, bispecific antibodies, antibodies or antibody fragment compounds or antibody conjugates bound to proteins other than antibodies, antibody enzymes, nanobodies, tandem scFv, bispecific Examples include tandem scFv, Diabody, VHH and the like.
- the term "antibody” also includes an antibody fragment and / or a derivative unless otherwise specified.
- a monoclonal antibody is classically an antibody molecule obtained from a clone derived from a single antibody-producing cell, but is a single type of antibody molecule containing a combination of VH and VL having a specific amino acid sequence. It means that.
- a monoclonal antibody it is possible to obtain a nucleic acid molecule having a gene sequence encoding an amino acid of the protein of the antibody, and it is also possible to prepare an antibody by genetic engineering using such a nucleic acid molecule.
- genetic information such as H chain, L chain, their variable regions and CDR sequences can be used to modify the antibody to improve the binding property and specificity, and from animal antibodies such as mice to human type.
- Producing an antibody having a structure suitable for use as a therapeutic agent by modifying it into an antibody is a technique well known to those skilled in the art in this field. It is also possible to obtain a human monoclonal antibody by using a non-human-transgenic animal into which a human antibody gene has been introduced as an animal that sensitizes the antigen. In addition, as a method that does not require sensitization to animals, a phage library (human antibody phage display) that expresses the antigen-binding region of a human antibody or a part thereof is used and specifically with the corresponding antigen.
- a phage library human antibody phage display
- a person skilled in the art can appropriately perform a technique for obtaining a phage clone consisting of an antibody to be bound or a specific amino acid sequence and producing a human antibody from the information (see, for example, Non-Patent Document 17 and the like). Further, when designing an antibody to be administered to an animal other than human, a person skilled in the art can design it by appropriately using the amino acid sequence information of CDR and the variable region, as in the technique of humanization. ..
- the antibodies of the invention are the complementarity determining regions (CDRs) of the heavy and light chains derived from the mouse parent antibody IGF11-16 and the frames of the heavy and light chains derived from the human antibody.
- CDRs complementarity determining regions
- Anti-IGF-1 receptor humanization comprising working regions (FRs) and at least one CDR containing at least one amino acid residue substitution against the corresponding CDR of the mouse parent antibody IGF11-16. It is an antibody.
- the heavy and light chain complementarity determining regions are derived from the corresponding CDRs of the mouse parent antibody IGF11-16, respectively.
- the mouse parent antibody "IGF11-16” is an anti-IGF-1 receptor monoclonal mouse antibody previously produced by the present inventors as described above (Patent Document 1).
- "derived" from the CDR of the mouse parent antibody means that the amino acid sequence of each CDR of the antibody of this embodiment is usually 75% or more of the amino acid sequence of the corresponding CDR of the mouse parent antibody IGF11-16.
- the antibody of this embodiment requires that at least one of the CDRs comprises the substitution of at least one amino acid residue with respect to the corresponding CDR of the mouse parent antibody IGF11-16.
- the amino acid sequence of the heavy chain CDR-2 (CDR-H2)
- they are homologous (preferably the same) except for the difference of 3 amino acid residues or less, and further 2 amino acid residues or less.
- each framework region (FR) of heavy and light chains is derived from the corresponding FR of each class of human immunoglobulin.
- "derived" from the FR of a human immunoglobulin means that the amino acid sequence of each FR of the antibody of this embodiment is usually 80% or more, particularly 85, with the amino acid sequence of the corresponding FR of the human immunoglobulin. % Or more, and even 90% or more homology (preferably identity), and / or usually 4 amino acid residues or less, especially 3 amino acid residues or less, and further excluding the difference of 2 amino acid residues or less. Means that they are homologous (preferably the same).
- Human immunoglobulin frameworks are available from public databases, and frameworks that are highly homologous to the mouse immunoglobulin framework can be selected.
- IgBLAST can be used for identification of amino acid sequences having homology (Non-Patent Document 16).
- the amino acid residue at position 25 of the heavy chain FR1 is preferably proline.
- the amino acid residue at position 25 of the heavy chain FR1 of the mouse parent antibody IGF11-16 is substituted with proline in the same manner as the mouse parent antibody IGF11-16.
- the activity is equal to or higher than that of the mouse parent antibody IGF11-16 ( It is preferable because the activity ratio can be exhibited within ⁇ 20% to the same extent.
- an evolutionary engineering method of an antibody can be used using the sequence of the heavy chain and the light chain derived from the humanized antibody of the present invention as a template.
- methods such as a site-specific mutagenesis method for CDR, a random mutagenesis method, chain shuffling, and CDR walking are used.
- Random mutagenesis is a method of introducing a random mutation into a specific gene DNA to prepare a mutant.
- a base mutation is introduced by selecting a condition with low replication strictness at the time of DNA amplification (error-prone PCR). Mutations are introduced at arbitrary sites for the entire area of DNA amplified by the PCR method.
- the target gene can be first cut into pieces, and then the mutation can be introduced in the same manner by the PCR method.
- Chain shuffling is to construct a library in which one of the VH or VL genes in the antibody variable region is immobilized and the other is bound to the V gene library, expressed on phage, and the original antigen is expressed. It is a method of screening a combination of antibody variable regions having high specificity for. It is the method of choice for in vitro affinity maturation of antibodies obtained from naive / non-immune libraries.
- CDR walking introduces random mutations into each CDR of the VH and VL genes, selects antibodies with strong binding by adjusting the selection conditions from the population of the mutants, and combines the selected CDRs. It is a method to obtain a clone with a very high binding force. In general, random mutations are often introduced and examined only in CDR3.
- the antibody of the present invention has a specific amino acid sequence as each CDR sequence. Specifically, it is as follows.
- identity of an amino acid sequence means the ratio of matching amino acid residues
- similarity means the ratio of matching or similar amino acid residues. do. Homology and identity can be determined, for example, by the BLAST method (the default condition of NCBI's BLAST).
- similar amino acid residue as used herein means an amino acid residue having a side chain having similar chemical properties (eg, charge or hydrophobicity). Examples of similar amino acid residues include the following groups. For example, according to the following group, substituting alanine for a similar amino acid residue means substituting for a valine, leucine, isoleucine or methionine residue.
- Amino acid residues having an aliphatic side chain alanine (Ala or A), valine (Val or V), leucine (Leu or L), isoleucine (Ile or I) and methionine (Met or M) residues.
- Amino acid residues having an aliphatic hydroxyl side chain serine (Ser or S) and threonine (Thr or T) residues.
- Amino acid residues having an amide-containing side chain asparagine (Asn or N) and glutamine (Gln or Q) residues.
- Amino acid residues having an aromatic side chain phenylalanine (Phe or F), tyrosine (Tyr or Y), tryptophan (Trp or W) and histidine (His or H) residues.
- Amino acid residues having a basic side chain lysine (Lys or K), arginine (Arg or R) and histidine (His or H) residues.
- Amino acid residues having an acidic side chain aspartic acid (Asp or D) and glutamic acid (Glu or E) residues.
- Amino acid group having a sulfur-containing side chain cysteine (Cys or C), and methionine (Met or M) residue.
- the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence in which any one of the amino acid residues of SEQ ID NO: 1 is substituted is preferable.
- the CDR-H1 sequence preferably has 80% or more homology (preferably identity) with SEQ ID NO: 1.
- the CDR-H1 sequence is an amino acid sequence in which the Trp at position 3 of SEQ ID NO: 1 is maintained or substituted with a similar amino acid residue, and any one other than the amino acid residue at position 3 is 1
- the amino acid residue at the site is substituted or that the amino acid sequence has an amino acid sequence having 80% or more homology (preferably identity) with SEQ ID NO: 1.
- An example of the nucleic acid base sequence corresponding to the amino acid sequence of SEQ ID NO: 1 is shown in SEQ ID NO: 2.
- the CDR-2 (CDR-H2) sequence of the heavy chain variable region includes the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 5, or any one, two, or three locations of SEQ ID NO: 3 or SEQ ID NO: 5. Amino acid sequences substituted with amino acid residues are preferred. Alternatively, the CDR-H2 sequence preferably has 82% or more homology (preferably identity) with SEQ ID NO: 3 or SEQ ID NO: 5.
- Glu at position 1 and Asn at position 3 of SEQ ID NO: 3 are maintained or replaced with similar amino acid residues, and Asn at position 6 is maintained, or An amino acid sequence substituted with Ser or Gln, wherein any one, two, or three amino acid residues other than the amino acid residues at the 1, 3, and 6 positions are substituted or replaced. It is preferable to have an amino acid sequence having 82% or more homology with SEQ ID NO: 3.
- Glu at position 1 and Asn at position 3 of SEQ ID NO: 5 are maintained, respectively, or are replaced with similar amino acid residues, and Ser at position 6 is maintained, or An amino acid sequence substituted with Asn or Gln, wherein any one, two, or three amino acid residues other than the amino acid residues at the 1, 3, and 6 positions are substituted or replaced. It is preferable to have an amino acid sequence having 82% or more homology with SEQ ID NO: 5. Examples of nucleic acid base sequences corresponding to the amino acid sequences of SEQ ID NOs: 3 and 5 are shown in SEQ ID NOs: 4 and 6, respectively.
- the amino acid sequence of SEQ ID NO: 7 or the amino acid sequence in which any one or two amino acid residues of SEQ ID NO: 7 are substituted is preferable.
- the CDR-H3 sequence preferably has 75% or more homology (preferably identity) with SEQ ID NO: 7.
- the CDR-H3 sequence is an amino acid sequence in which Arg at position 4 of SEQ ID NO: 7 is maintained or substituted with a similar amino acid residue, and any one other than the amino acid residue at position 4 is 1 It is preferable that the amino acid residue at one or two sites is substituted, or that the amino acid sequence has 75% or more homology (preferably identity) with SEQ ID NO: 7.
- An example of the nucleic acid base sequence corresponding to the amino acid sequence of SEQ ID NO: 7 is shown in SEQ ID NO: 8.
- the amino acid sequence of SEQ ID NO: 9 or the amino acid sequence in which any one or two amino acid residues of SEQ ID NO: 9 are substituted is preferable.
- the CDR-L1 sequence preferably has 81% or more homology (preferably identity) with SEQ ID NO: 9.
- the CDR-L1 sequence is an amino acid sequence in which the Trp at position 9 of SEQ ID NO: 9 is maintained or is substituted with a similar amino acid residue, and any one other than the amino acid residue at position 9 is 1 It is preferable that the amino acid residue at one or two sites is substituted, or that the amino acid sequence has 81% or more homology (preferably identity) with SEQ ID NO: 9.
- An example of the nucleic acid base sequence corresponding to the amino acid sequence of SEQ ID NO: 9 is shown in SEQ ID NO: 10.
- the amino acid sequence of SEQ ID NO: 11 or the amino acid sequence in which any one amino acid residue of SEQ ID NO: 11 is substituted is preferable.
- the CDR-L2 sequence preferably has 85% or more homology (preferably identity) with SEQ ID NO: 11.
- An example of the nucleic acid base sequence corresponding to the amino acid sequence of SEQ ID NO: 11 is shown in SEQ ID NO: 12.
- the amino acid sequence of SEQ ID NO: 13 or the amino acid sequence in which any one or two amino acid residues of SEQ ID NO: 13 are substituted is preferable.
- the CDR-L3 sequence preferably has 77% or more homology (preferably identity) with SEQ ID NO: 13.
- An example of the nucleic acid base sequence corresponding to the amino acid sequence of SEQ ID NO: 13 is shown in SEQ ID NO: 14.
- the antibody of the present invention preferably has the following combination of CDR sequences. That is, as the CDR-H1 sequence, the amino acid sequence of SEQ ID NO: 1, as the CDR-H2 sequence, the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 5, as the CDR-H3 sequence, as the amino acid sequence of SEQ ID NO: 7, and as the CDR-L1 sequence.
- the amino acid sequence of SEQ ID NO: 9, the CDR-L2 sequence is preferably a combination of the amino acid sequence of SEQ ID NO: 11 and the CDR-L3 sequence is preferably a combination of the amino acid sequence of SEQ ID NO: 13.
- Non-Patent Document 13 Kabat method
- Non-Patent Document 14 Chothia method
- Non-Patent Document 15 a method obtained by further improving these methods
- These methods are common technical knowledge for those skilled in the art in this area, but for example, you can get an overview from the Internet homepage (http://www.bioinf.org.uk/abs/) of Dr. Andrew CR Martin's Group. It is also possible.
- Example 4 by performing an alanine scan, it is possible to identify a site important for binding activity in the amino acid sequence of CDR. From the results, it is clear that the amino acid residues shown in Tables 7 and 8 described later are extremely important. Substitution of at least the amino acid residue at this site with an amino acid other than an amino acid having similar properties is considered to lead to a decrease in binding property. Conversely, it may be possible to achieve improved affinity by substituting for amino acids with similar properties. On the other hand, of the 54 regions of the CDR regions substituted with alanine, 44 sites showed 80% or more of the binding activity even after the substitution with alanine. This suggests that amino acid substitutions at these sites do not significantly affect binding activity. In this way, by searching the amino acid sequences of the CDR regions and identifying the sites involved in binding, immunogenicity can be reduced, physical properties can be improved, and binding can be improved while maintaining binding. It is possible to do.
- the antibody of the present invention preferably has a specific amino acid sequence as a heavy chain variable region and a light chain variable region. Specifically, it is as follows. In the present disclosure, “one place or several places” means one place, two places, three places, four places, five places, six places, seven places, eight places, nine places, or ten places, unless otherwise specified. It shall refer to any of the locations.
- the antibody of the present invention has an amino acid sequence of SEQ ID NO: 47 or an amino acid sequence in which one or several amino acid residues are substituted, deleted, or added in the amino acid sequence of SEQ ID NO: 47 as a heavy chain variable region. Is preferable. Alternatively, it is preferable to have an amino acid sequence having 90% or more homology (preferably identity) with SEQ ID NO: 47 as the heavy chain variable region.
- VH13_PN SEQ ID NO: 43
- VH13_PS SEQ ID NO: 47
- VH23_PN SEQ ID NO: 49
- VH23_PS SEQ ID NO: 53
- VH25_PN SEQ ID NO: 55
- VH25_PS SEQ ID NO: 59
- nucleic acid base sequences corresponding to the amino acid sequences of SEQ ID NOs: 43, 47, 49, 53, 55, and 59 are shown in SEQ ID NOs: 44, 48, 50, 54, 56, and 60, respectively.
- the antibody of the present invention contains, as a light chain variable region, an amino acid sequence of SEQ ID NO: 67 or an amino acid sequence in which one or several amino acid residues are substituted, deleted, or added in the amino acid sequence of SEQ ID NO: 67. It preferably has an amino acid sequence. Alternatively, it is preferable to have an amino acid sequence having 90% or more homology (preferably identity) with SEQ ID NO: 67 as the light chain variable region.
- the light chain variable region may have the amino acid sequence of VL13 (SEQ ID NO: 61), VL14 (SEQ ID NO: 63), VL22 (SEQ ID NO: 65), VL23 (SEQ ID NO: 67), or VL24 (SEQ ID NO: 69). preferable.
- VL22 (SEQ ID NO: 65), VL23 (SEQ ID NO: 67), or VL24 (SEQ ID NO: 69).
- Examples of nucleic acid base sequences corresponding to the amino acid sequences of SEQ ID NOs: 61, 63, 65, 67, and 69 are shown in SEQ ID NOs: 62, 64, 66, 68, and 70, respectively.
- the antibody of the present invention has any of the above-mentioned amino acid sequences as the heavy chain variable region and the light chain variable region, respectively.
- a particularly preferable antibody of the present invention is an antibody having an amino acid sequence of VH13_PS (SEQ ID NO: 47) as a heavy chain variable region and an amino acid sequence of VL23 (SEQ ID NO: 67) as a light chain variable region (hereinafter referred to as "hIGF13_PS").
- hIGF25_PS an antibody having the amino acid sequence of VH25_PS (SEQ ID NO: 59) as the heavy chain variable region and the amino acid sequence of VL23 (SEQ ID NO: 67) as the light chain variable region (hereinafter referred to as "hIGF25_PS"). There is.).
- the amino acid sequence of each constant region of the heavy chain and the light chain of the antibody of the present invention is selected from, for example, the amino acid sequences of each class of human IgG, IgA, IgM, IgE, and IgD, and the amino acid sequences of variants thereof. It is possible to do.
- the amino acid sequence of the heavy chain constant region of the antibody of the present invention is an amino acid sequence of the heavy chain constant region of the human IgG4 class, or an amino acid sequence in which 1 to 10 amino acids thereof are substituted. Is preferable (Non-Patent Documents 19 and 20).
- the amino acid sequence of the heavy chain constant region of the antibody of the present invention is an amino acid sequence of the heavy chain constant region of the human IgG1 class, or an amino acid sequence in which 1 to 10 amino acids thereof are substituted. Is preferable (Non-Patent Documents 19 and 20).
- the antibody of the present invention is an antibody that causes an antigen-antibody reaction with a human IGF-1 receptor.
- antigen-antibody reaction means that an antibody binds to an IGF-1 receptor with an affinity of equilibrium dissociation constant (KD) of 1 ⁇ 10 -7 M or less.
- KD equilibrium dissociation constant
- the antibody of the present invention preferably binds to the IGF-1 receptor with a KD of usually 1 ⁇ 10 -7 M or less, particularly 1 ⁇ 10 -8 M or less, and further preferably 1 ⁇ 10 -9 M or less. .. Most preferably, it is 1 ⁇ 10 -10 M or less.
- the antibody of the present invention preferably specifically binds to the extracellular domain of the human IGF-1 receptor having the amino acid sequence of SEQ ID NO: 71.
- an antibody having "specificity" to an antigen means that a high antigen-antibody reaction occurs between the antibody and the antigen.
- IGF-1 receptor-specific antibody refers to a higher-order structure of the IGF-1 receptor at a concentration that exhibits a significant antigen-antibody reaction with cells expressing the IGF-1 receptor.
- An antibody having an antigen-antibody reactivity to INSR having similarity of 1/100 or less.
- the measurement of the antigen-antibody reaction can be carried out by a person skilled in the art by appropriately selecting the binding measurement in a solid phase or liquid phase system.
- Such methods include enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), surface plasmon resonance (SPR), and fluorescence resonance energy transfer method.
- ELISA enzyme-linked immunosorbent assay
- EIA enzyme immunoassay
- SPR surface plasmon resonance
- fluorescence resonance energy transfer method Fluorescence resonance energy transfer: FRET
- emission resonance energy transfer method luminescence resonance energy transfer: LRET
- the antibody and / or antigen is labeled with an enzyme, a fluorescent substance, a luminescent substance, a radioactive isotope, or the like, and the physical and / or chemical properties of the labeled substance. It is also possible to detect an antigen-antibody reaction using a measurement method suitable for the above.
- the antibody of the present invention has an IGF-1 receptor signal activating ability equal to or higher than that of the mouse parent antibody IGF11-16.
- “equivalent” in the ability to activate the IGF-1 receptor signal means that the EC 50 value is within 2 times and / or the E max value is within ⁇ 20%.
- the antibody of the present invention preferably has a proliferation activity equal to or higher than that of the mouse parent antibody IGF11-16.
- “equivalent” in proliferative activity means that the EC 50 value is within 10 times and the E max value is 90% or more in the myoblast proliferation test.
- the antibody of the present invention preferably has a binding affinity for the recombinant soluble IGF-1 receptor equal to or higher than that of the mouse parent antibody IGF11-16.
- "equivalent" binding affinity to recombinant soluble IGF-1 receptor is compared to mouse parent antibody IGF11-16 in the binding affinity analysis to recombinant soluble IGF-1 receptor by BIACORE. If this is the case, it means that the KD value is in the range of 1/3 or more to 3 times or less.
- the antibody of the present invention has a long half-life in blood and exhibits a muscle mass increasing effect by a single administration to an animal.
- the anti-IGF-1 receptor humanized antibody of the present invention was administered once to a guinea pig or a crab monkey as shown in Examples described later, and the IGF-1 was obtained. It showed the same level of muscle mass-increasing effect as when it was continuously administered.
- the antibody of the present invention can induce a muscle mass increasing action without inducing hypoglycemic symptoms in normal mammals. According to one aspect, it is preferable that the antibody of the present invention can induce a growth plate cartilage elongation action without inducing hypoglycemic symptoms in a pituitary excision model animal.
- the "blood glucose symptom” means, in the case of humans, symptoms such as cold sweat, palpitation, consciousness disorder, convulsions, and tremors of limbs caused by hypoglycemia. In vertebrates such as monkeys, a decrease in locomotor activity appears as an initial symptom, and when the symptom is strong, there is almost no movement, and when the blood glucose level drops, consciousness disorder occurs, leading to death.
- the antibody of the present invention is administered to a vertebrate at a dose that induces an increase in vertebrate muscle mass and / or length, more preferably at a dose that is 10-fold or more higher than that dose. Even it has no effect on lowering the blood glucose level of the vertebrate. Further, according to one aspect, the antibody of the present invention was administered to the vertebrate so as to have a blood exposure amount of 10 times or more the effective dose for inducing an increase in muscle mass and / or body length of the vertebrate.
- the antibody of the present invention does not induce hypoglycemic symptoms even when administered at a dose of 10 mg / kg in guinea pigs and cynomolgus monkeys, as shown in Examples described later. rice field.
- the anti-IGF-1 receptor humanized antibody of the present invention can be used for various diseases associated with IGF-1 receptors such as disused muscular atrophy and short stature, which are expected for IGF-1. It has the potential to be a therapeutic or prophylactic agent, overcomes the problem of IGF-1 and has a hypoglycemic effect, and can prolong the half-life in blood.
- the antibody of the present invention is a homozygous receptor in which the IGF-1 receptor forms a dimer by binding to the extracellular domain of the IGF-1 receptor, or the IGF-1 receptor and INSR are dimeric. It is thought to activate the heteromorphic receptors that formed the body.
- Anti-Drug Antibody affects the efficacy and pharmacokinetics of therapeutic antibodies and can sometimes lead to serious side effects, so the usefulness and efficacy of therapeutic antibodies in clinical practice is ADA. Can be limited by the production of. Although many factors affect the immunogenicity of therapeutic antibodies, the importance of effector T cell epitopes present in therapeutic proteins has been widely reported. Epibase (Lonza), iTope / TCED (Antitope), EpiMatrix (EpiVax) and the like have been developed as in silico tools for predicting T cell epitopes.
- Non-Patent Document 21 the presence of T cell epitopes in each amino acid sequence can be predicted (Non-Patent Document 21), and potential immunogenicity can be evaluated.
- the potential immunogenicity was evaluated using Epibase (Lonza).
- the NS sequence (heavy chain positions 55 and 56) was present in the heavy chain CDR-2 (CDR-H2) region of the mouse parent antibody IGF11-16, so that asparagine (N) at the heavy chain position 55 was present.
- the asparagine (N) was replaced with serine (S) in consideration of the risk of deamidation and conversion to aspartic acid (D).
- the anti-IGF-1 receptor humanized antibody of the present invention has a purity of 95% or more using a sample obtained by using a PBS solution of the present antibody, setting the temperature to 37 ° C. and incubating for 1 month. The stability of the physical properties was confirmed by confirming that no agglomerates were formed.
- the antibody of the present invention uses the CR domain of the IGF-1 receptor as an epitope.
- the antibody of the present invention binds to an epitope or a vicinity thereof containing a peptide having an amino acid sequence (ProSerGlyPheIleArgAsnGlySerGlnSerMet) corresponding to amino acid numbers 308 to 319 in the amino acid sequence (SEQ ID NO: 71) of the human IGF-1 receptor. do.
- the antibody of the present invention is a homozygous receptor in which the IGF-1 receptor forms a dimer by binding to the CR domain of the IGF-1 receptor, or a dimer of the IGF-1 receptor and INSR. It is thought to activate the heterozygous receptor that formed the.
- the agonist antibody of the present invention is preferably a human IgG class or a variant thereof, and is preferably a human IgG4 subclass or a variant thereof, or a human IgG1 subclass or a variant thereof.
- the stabilized IgG4 constant region contains proline at position 241 of the hinge region by Kabat's system (Non-Patent Document 22). This position corresponds to the position 228 of the hinge region by the EU numbering method (Non-Patent Document 13). In human IgG4, this residue is generally serine and the substitution of serin with proline can induce stabilization.
- the N297A mutation can be incorporated into the constant region of IgG1 to minimize the ability to bind to Fc receptors and / or immobilize complement.
- the binding to FcRn can be regulated and the half-life in blood can be lengthened by introducing an amino acid substitution into the constant region.
- amino acid substitutions in the constant region are not limited to these examples.
- the agonist antibody of the present invention specifically and strongly binds to the IGF-1 receptor, and has an action of enhancing myoblast proliferation from an extremely low concentration in vitro.
- the agonist antibody of the present invention exhibits a muscle mass-increasing effect similar to that of continuous administration of IGF-1 when administered once to an animal.
- the agonist antibody of the present invention has a long half-life in blood and can exhibit a muscle mass-increasing effect by a single administration to an animal.
- the muscle mass-increasing effect and the muscle mass-increasing effect when IGF-1 is continuously administered are shown.
- the agonist antibody of the present invention is characterized in that it does not have a hypoglycemic effect at a dose showing a muscle mass increasing effect.
- IGF-1 has a significant hypoglycemic effect when administered at a dose showing a muscle mass increasing effect.
- the agonist antibody of the present invention has no effect of lowering the blood glucose level of the vertebrate at a dose that induces an increase in vertebrate muscle mass and / or body length.
- the agonist antibodies of the invention are vertebrate blood glucose, even when administered to a blood exposure of at least 10 times the effective dose that induces an increase in vertebrate muscle mass and / or length. It has no effect of lowering the value.
- the agonist antibody of the present invention in fact, in guinea pigs or crab monkeys, even when the agonist antibody of the present invention is administered so as to have a blood exposure of 10 times or more the effective dose that induces an increase in muscle mass, hypoglycemia and No hypoglycemic symptoms were observed.
- the agonist antibody of the present invention has the potential to be a therapeutic or prophylactic agent for various diseases related to the IGF-1 receptor such as sarcopenia, disuse muscular atrophy, Kakexia and short stature.
- various diseases related to the IGF-1 receptor such as sarcopenia, disuse muscular atrophy, Kakexia and short stature.
- the anti-IGF-1 receptor humanized antibody of the present invention is an anti-IGF-1 receptor antagonist antibody having excellent activity and specificity by utilizing the properties of the variable region having extremely high binding and specificity. can do. In that case, in addition to IgG, it is conceivable to use it in the form of Fab, Fv, scFv, VHH, but the present invention is not limited to this.
- the anti-IGF-1 receptor antagonist antibody thus produced can be evaluated using, for example, suppressing the IGF-1-dependent cell proliferation activity in a cancer cell line as an index.
- the anti-IGF-1 receptor antagonist antibody thus selected is expected as an anti-cancer agent and an ameliorating and therapeutic agent for diseases and pathological conditions associated with abnormal cell proliferation.
- bispecific antibodies and multispecific antibodies can be constructed by fusing with various antibodies recognizing other antigens or epitopes directly or via a linker or the like.
- IgG immunoglobulin G
- Bispecific antibodies and multispecific antibodies containing anti-IGF-1 receptor antagonist antibodies thus prepared can suppress IGF-1-dependent cell proliferation activity in cancer cell lines, for example. It can be evaluated as an index. Bispecific antibodies and multispecific antibodies containing the anti-IGF-1 receptor antagonist antibody thus selected are expected to be anti-cancer agents and ameliorating and therapeutic agents for diseases and pathological conditions associated with abnormal cell proliferation. Will be done.
- the anti-IGF-1 receptor antagonist antibody of the present invention is expected as a therapeutic agent for a disease in which a pathological condition is induced by activation of an IGF-I receptor signal.
- the ligands capable of activating the IGF-I receptor mainly include IGF-1, IGF-2, Insulin and the like, and RTK (receptor type tyrosine kinase) formed into a heterodimer with the IGF-1 receptor. It also includes ligands (such as EGF) and ligands for other receptors that crosstalk (such as TSH).
- the antibody of the present invention has an action of suppressing the IGF-1 receptor signal activated by these ligands (has an allosteric antagonist action.
- the antibody of the present invention binds to the IGF-1 receptor. It suppresses over-induced IGF-1 receptor signal activity and can be used to treat or prevent diseases induced by abnormally activated IGF-1 receptor.
- Signal activation inhibitory ability is mouse. It is preferable to have the same or higher level as the parent antibody IGF11-16.
- the signal activation inhibitory ability "equivalent to the mouse antibody IGF11-16" is defined as IGF-1, IGF-2, or IGF- such as Insulin in myoblast proliferation. It means an activity that suppresses the maximum cell proliferation activity that can be induced by a ligand capable of activating an I receptor by 10% or more, preferably 25% or more, particularly preferably 35% or more.
- diseases induced by abnormal activation of IGF-1 receptors include liver cancer, neuroblastoma, rhabdomyomyoma, osteosarcoma, pediatric cancer, apical giant disease, and ovary. Cancer, pancreatic cancer, benign prostatic hypertrophy, breast cancer, prostate cancer, bone cancer, lung cancer, colorectal cancer, cervical cancer, synovial sarcoma, bladder cancer, gastric cancer, Wilms tumor, metastatic cartinoids and Diarrhea associated with vasoactive intestinal peptide secretory tumors, bipoma, Werner-Morison syndrome, Beckwith-Wedemann syndrome, kidney cancer, renal cell cancer, transitional epithelial cancer, Ewing sarcoma, leukemia, acute lymphoblastic leukemia , Brain tumor, glioblastoma, non-glioblastic brain tumor, medullary tumor, pituitary adenoma, vestibular neurasemia, undifferentiated ectodermal tumor
- Anti-IGF-1 receptor humanized antibody as a local delivery tool
- Local delivery of drugs and antibodies to IGF-1 receptor-expressing cells, expression tissues, etc. is possible by utilizing the extremely high binding property and specificity of the anti-IGF-1 receptor antibody of the present invention.
- the anti-IGF-1 receptor antibody of the present invention it is conceivable to use it in the form of Fab, Fv, scFv, VHH in addition to IgG, but the present invention is not limited thereto. ..
- the drug can be delivered locally, so that the drug can exert its specific effect at a lower dose, which is a side effect. It also leads to the reduction of.
- the drug or antibody to which the anti-IGF-1 receptor humanized antibody of the present invention thus prepared is ligated as a delivery tool is, for example, an IGF-1 receptor-expressing cancer cell when the drug is an apoptosis-inducing agent. It can be evaluated using the induction of apoptosis in the strain as an index.
- the drug or antibody to which the anti-IGF-1 receptor antibody thus selected is ligated is expected as an anti-cancer drug or an ameliorating and therapeutic drug for diseases and pathological conditions associated with abnormal cell proliferation.
- the anti-IGF-1 receptor antibody of the present invention and an antibody that competitively binds to the IGF-1 receptor are also included in the scope of the present invention.
- “competitive binding” means a phenomenon in which when a plurality of types of monoclonal antibodies coexist with an antigen, the binding of one antibody to the antigen is inhibited by the binding of the other antibody to the antigen.
- concentration concentration
- concentration concentration of a monoclonal antibody
- the monoclonal antibody that competitively binds to the anti-IGF-1 receptor antibody of the present invention has an IC 50 of usually 1000 nM or less when the antigen-antibody binding is detected using the anti-IGF-1 receptor antibody of the present invention at 10 nM. Above all, it refers to an antibody of 100 nM or less, and further 10 nM or less.
- a part or all of the antibody to be used is labeled with an enzyme, a fluorescent substance, a luminescent substance, a radioactive isotope, etc., and the measurement is suitable for the physical and / or chemical properties of the labeled substance. It is also possible to make the measurement by detecting it using a method.
- the antibodies of the invention have a cross-reactivity to the IGF-1 receptor of other vertebrates.
- the cross-reaction means that the antibody exhibits binding property to an IGF-1 receptor of another animal species different from the animal species (for example, human) of the IGF-1 receptor that undergoes an antigen-antibody reaction.
- the anti-IGF-1 receptor humanized antibody of the present invention exhibits cross-reactivity with IGF-1 receptors such as guinea pigs, monkeys and rabbits in addition to humans. On the other hand, it does not show cross-reactivity with mouse and rat IGF-1 receptors.
- cells and animals expressing the IGF-1 receptor with which the antibody of the present invention cross-reacts by genetically engineering the cells and animals using a species of animal that does not cross-react with the antibody of the present invention. It is also possible to make.
- the anti-IGF-1 receptor humanized antibody of the present invention has an extremely strong binding affinity at a level equal to or higher than that of the mouse parent antibody IGF11-16 (Patent Document 1).
- the binding affinity can be evaluated, for example, by using the extracellular region of the recombinant IGF-1 receptor as an antigen and performing SPR (surface plasmon resonance) analysis.
- SPR surface plasmon resonance
- BIACORE is used to raise the reaction temperature to 40 ° C. to keep the amount of antigen fixed low to analyze the monovalent binding affinity, but the method is not limited to this method. Any analysis method that can quantitatively evaluate the strong binding affinity may be used.
- the anti-IGF-1 receptor humanized antibody of the present invention has a level equal to or higher than that of the mouse parent antibody IGF11-16 (Patent Document 1) by using IGF-1 receptor signal activation as a primary evaluation system. It was obtained by selecting a humanized antibody.
- IGF-1 receptor signaling activation was a commercially available PathHunter (TM) IGF1R Functional Assay (DiscoverX Co.).
- TM PathHunter
- phosphorylation directly under the IGF-1 receptor signal can be evaluated as enzyme activity, a chemiluminescent substance is used as a substrate, and the signal intensity is measured by the luminescence intensity.
- an adapter protein SHC1-EnzymeAcceptor (EA) fusion protein having an SH2 domain that binds to the intracellular tyrosine kinase of the IGF-1 receptor and the IGF-1 receptor was forcibly expressed in HEK293 cells.
- a cell line was used. In this cell line, ligand binding to the IGF-1 receptor causes receptor dimerization, followed by phosphorylation of the receptor to recruit adapter proteins with SH2 domains and accept receptor signals.
- a transduction complex is formed, facilitating the binding of EA to spatially adjacent tyrosine kinases and reconstitution of active ⁇ -galactosidase.
- the method for evaluating the IGF-1 receptor signal is not limited to this method, and any system may be used as long as it can directly or indirectly and quantitatively detect IGF-1 receptor tyrosine phosphorylation.
- Human myoblast proliferation was evaluated as a secondary evaluation system for the humanized antibody of the present invention, and humanized antibodies having the same or higher agonist activity in the same concentration range as the mouse parent antibody IGF11-16 (Patent Document 1) were narrowed down. is. It was confirmed that the humanized antibody of the present invention thus selected did not show a hypoglycemic effect in vivo and had a muscle mass increasing effect. That is, the anti-IGF-1 receptor humanized antibody of the present invention in one embodiment has a growth-inducing activity of vertebrate-derived cells.
- the "vertebrate-derived cell” is preferably a cell derived from a mammal, a bird, a reptile, an amphibian or a fish, more preferably a cell derived from a mammal or a bird, and even more preferably.
- cells and animals modified to express certain IGF-1 receptors that are cross-reactive with the antibody of the present invention, or cells derived from the modified animals are also referred to as "cells derived from vertebrates" in the present disclosure. "include.
- primary cultured cells As cells for investigating the growth-inducing activity of vertebrate-derived cells in vitro, primary cultured cells, cell lines, or transformed cells of those cells can be used.
- primary cultured cell refers to a cell isolated from an organ or tissue of an organism, which is usually capable of subculture with a certain number of subcultures.
- Primary cultured cells derived from vertebrates can be obtained from vertebrate organs and tissues by a method such as enzymatic treatment, dispersion by a physical method, or an expand method. It is also possible to use organs and tissues obtained from vertebrates, or fragments thereof.
- the organs and tissues that prepare these primary cells are preferably endocrine tissues such as thyroid gland, parathyroid gland and adrenal gland, immune tissues such as pits, tonsils, lymph nodes and spleen, respiratory organs such as trachea and lung, and stomach.
- the primary cultured cells used for investigating the growth-inducing activity of the antibody of the present invention include cells that express the IGF-1 receptor and whose growth is induced by IGF-1 that binds to the IGF-1 receptor. Used.
- skeletal myoblasts which are primary cultured cells isolated from muscle tissue, are used.
- primary cultured cells derived from humans or animals it is also possible to obtain and use commercially available cells.
- Human primary culture cells for example, ATCC (R), available ECACC, Lonza, Gibco (R), Cell Applications, ScienCell research laboratories , the organizations and companies such PromoCell.
- Examples of the method for investigating the cell proliferation-inducing activity of the antibody of the present invention in vertebrate-derived cells include measurement of cell number measurement, measurement of DNA synthesis amount, measurement of change amount of metabolic enzyme activity, and the like.
- a method for measuring the number of cells there are a method using a blood cell count board and a method using a cell number measuring device such as a coulter counter, and as a method for measuring the amount of DNA synthesis, [3H] -thymidine or 5-bromo-
- a method for measuring by taking in 2'-deoxyuridine (BrdU) and a method for observing the amount of change in metabolic enzyme activity there are colorimetric quantitative methods such as MTT method, XTT method and WST method. It can also be carried out by other methods.
- the cell proliferation-inducing activity was determined by the fact that the cell proliferation was increased when the antibody of the present invention was reacted with the cultured cells used in the test as compared with the case where the antibody was not reacted. can. In this case, it is convenient to evaluate the activity by reacting IGF-1, which is a ligand of the original IGF-1 receptor, under the same conditions as a control of the inducing activity.
- the EC 50 value is the concentration at which 50% of the maximum growth-inducing activity is exhibited when the antibody of the present invention and IGF-1 are reacted with the cultured cells to be tested at different concentrations. ..
- cell proliferation-inducing activity of the antibodies of the present invention are The EC 50 values equal to or larger than that of the IGF-1, more preferably antibodies of the present invention
- the EC 50 value is 1/10 or less of IGF-1, more preferably 1/20 or less, and even more preferably the EC 50 value of the antibody of the present invention is 1/50 or less of IGF-1.
- the EC 50 value of the antibody of the present invention was preferably 0.5 nM or less, more preferably 0.3 nM or less, still more preferable. Is 0.1 nM or less.
- the antibody of the present invention is administered to a vertebrate, and changes in the mass, size, cell number, etc. of an organ or tissue in the whole administered individual or in the administered individual are observed.
- To measure, or to use an animal transplanted with the vertebrate cell measure changes in the mass, size, number of cells, etc. of the transplant containing the transplanted vertebrate cell in the transplanted individual. You can find out at. In the measurement of the whole individual, measurement of body weight, body length, circumference of limbs, etc., body composition measurement by impedance method, creatinine, height coefficient, etc. are used.
- the target organs, tissues, or grafts in an individual in animals other than humans, the target organs, tissues, or grafts are directly collected, and the mass, size, and number of cells contained are calculated.
- an X-ray image typified by the DXA (Dual-energy X-ray absorptiometry) method, image analysis by CT and MRI, and isotopes Or a contrast method using a tracer using a fluorescent substance or the like is used.
- DXA Direct-energy X-ray absorptiometry
- those skilled in the art can investigate the effect of the antibody of the present invention on the in vivo proliferation-inducing activity of vertebrate-derived cells by using other methods as appropriate.
- an individual to which the antibody of the present invention was administered and an individual to which an antibody other than the antibody of the present invention or another control substance was administered were used. It can be evaluated by comparing the results of measurement and the like by the method shown above.
- Example 14 guinea pig blood of the mouse antibody IGF11-16 antibody (Patent Document 1) which was the basis of the design of the antibody of the present invention and the antibodies hIGF13_PS and hIGF25_PS of the present invention. The kinetics were compared, and it was shown that the kinetics in the blood was improved compared with IGF11-16.
- One of the in vivo effects of the antibody of the present invention is the effect of increasing muscle mass and / or body length.
- IGF-1 In addition to acting on the proliferation and differentiation of the above-mentioned myoblasts in skeletal muscle, IGF-1 also has an action of thickening muscle fibers, and it is considered that IGF-1 has an effect of increasing muscle mass as such a comprehensive action. There is.
- the antibody of the present invention also has the effect of increasing the muscle mass of the animal when administered to the animal in the same manner as IGF-1.
- body composition measurement by the impedance method creatinine, height coefficient, etc. are used in the measurement of the whole individual, such as body weight, body length, and limb circumference.
- methods such as X-ray imaging images represented by the DXA (Dual-energy X-ray absorptiometry) method, image analysis by CT and MRI, and imaging methods using tracers using isotopes and fluorescent substances are used.
- Changes in muscle strength, etc. are also indicators.
- the effect of increasing muscle mass is to compare the increase in muscle mass between an individual who received the antibody of the present invention and an individual who did not receive the antibody, or administer the antibody of the present invention in one individual. It can be evaluated by comparing the muscle mass before and after administration.
- the effect of increasing muscle mass can be known if a difference in the increase in muscle mass is observed by administration of the antibody of the present invention.
- IGF-1 is also involved in bone growth and also has the function of increasing body length (height in the case of humans). Therefore, the antibody of the present invention also has an effect of increasing the body length when administered to an animal.
- the effect of increasing the body length by the antibody of the present invention can be measured by measuring the body weight, body length, perimeter of limbs, etc. of an individual.
- the antibody of the present invention is characterized in that it does not affect the blood glucose level in vertebrates.
- IGF-1 is known to cause a blood glucose lowering effect as part of the agonistic action on the IGF-1 receptor.
- the agonist antibody of the present invention which functions as an anti-IGF-1 receptor agonist antibody, has a blood exposure of 10 times or more the effective dose that induces an increase in muscle mass when administered parenterally to an animal. , Shows the feature that the blood glucose level does not fluctuate.
- the effect of the antibody of the present invention on vertebrates that does not induce a decrease in blood glucose can be evaluated, for example, in vitro.
- cells for investigating the feature of vertebrate-derived cells that do not affect the uptake of glucose into cells in vitro primary cultured cells, cell lines, or transformed cells of those cells can be used. It is possible.
- the effect on intracellular glucose uptake is such that the intracellular glucose uptake when the antibody of the present invention is reacted with the cultured cells used in the test is the same as when the antibody is not reacted. It can be judged by the existence. In this case, it is convenient to evaluate the activity by reacting IGF-1, which is a ligand of the original IGF-1 receptor, under the same conditions as a control of the inducing activity.
- the antibody of the present invention is administered to the vertebrate and the change in glucose content in an organ or tissue in the administered individual is measured. Can be done. In the measurement of the whole individual, measurement of blood glucose level and the like, hemoglobin A1C and the like using a glycated protein as an index are used. In the measurement of the amount of glucose uptake in an organ or tissue in an individual, in an animal other than human, the target organ or tissue is directly collected, and the glucose content or tracer is calculated.
- an X-ray image, image analysis by CT or MRI, a contrast method using a tracer using an isotope or a fluorescent substance, or the like is used. ..
- glucose clamp or the like is also an index.
- those skilled in the art can investigate the effect of the antibody of the present invention on glucose uptake in vivo by vertebrate-derived cells by using other methods as appropriate.
- the vertebrate when the antibody of the present invention is administered to a vertebrate, the vertebrate has the same dose, preferably 10 times or more the effective dose for inducing an increase in muscle mass of the vertebrate. It is characterized in that it does not fluctuate the blood glucose level.
- the animal for investigating the change in the blood glucose level of the antibody of the present invention in a vertebrate is preferably an animal belonging to a mammal, a bird, a reptile, an amphibian or a fish, and more preferably an animal belonging to a mammal or a bird. Even more preferred are humans, monkeys, rabbits, guinea pigs, cows, pigs, sheep, horses, dogs, rats, or mice.
- animals modified to express certain IGF-1 receptors that are cross-reactive with the antibody of the present invention can also be used as animals for examining changes in blood glucose levels of the antibody of the present invention in vertebrates. included.
- the colorimetric method, the electrode method, etc. are used as the invasive method, and the enzymes for detection include the glucose oxidase method (GOD method), the glucose dehydrogenase method (GDH method), etc.
- GOD method glucose oxidase method
- GDH method glucose dehydrogenase method
- an invasive method there is an optical measurement method and the like, but other methods can be appropriately selected by those skilled in the art.
- the blood glucose level is human, the normal range of the fasting blood glucose level is 100 mg / dL to 109 mg / dL.
- Adverse events due to drug administration to blood glucose level are hypoglycemia when the blood glucose level is lower than the range of 77 mg / dL to 55 mg / dL, and 109 mg / dL to 160 mg / dL. If the value is higher than the range, it is defined as hyperglycemia.
- No effect of drug administration on blood glucose level means that the blood glucose level after drug administration is in the range of above 55 mg / dL and below 160 mg / dL, more preferably above 77 mg / dL and below 109 mg / dL. Is to be within the range of.
- the blood glucose level differs depending on the animal to which it is administered, and the range of fluctuation thereof differs, and even in humans, the blood glucose level at the time of administration is not always in the range of the normal value.
- the blood glucose level of the vertebrate to which the antibody of the present invention was administered is preferably within 30%, more preferably within 20%, and even more preferably 10 as compared with the solvent administration control group. It means that the change is within%.
- the antibody of the present invention can be obtained by humanizing the mouse monoclonal antibody IGF11-16 (Patent Document 1) against the IGF-1 receptor. Replacing the CDR regions with a human framework by CDR graphing using a monoclonal antibody obtained from a non-human animal species is called humanization (Non-Patent Document 12). Furthermore, by three-dimensional structural analysis, in order to avoid amino acid substitution to reduce immunogenicity (T cell antigenicity) to humans and post-translational modification risk such as deamidation and oxidation while maintaining the three-dimensional structure. By introducing the amino acid substitution of, we will produce a humanized antibody that ensures manufacturability and clinical safety while maintaining activity.
- VH13_PN SEQ ID NO: 43
- VH13_PS VH13_PS as heavy chain variable regions.
- SEQ ID NO: 47 VH23_PN (SEQ ID NO: 49)
- VH23_PS SEQ ID NO: 53
- VH25_PN SEQ ID NO: 55
- VH25_PS SEQ ID NO: 59
- VL13 SEQ ID NO: 61
- Examples thereof include humanized antibodies having VL14 (SEQ ID NO: 63), VL22 (SEQ ID NO: 65), VL23 (SEQ ID NO: 67), or VL24 (SEQ ID NO: 69).
- the light chain variable region more preferably has VL22 (SEQ ID NO: 65), VL23 (SEQ ID NO: 67), or VL24 (SEQ ID NO: 69).
- the antibodies of the invention are not limited to them.
- the obtained anti-IGF-1 receptor humanized antibody it is also possible to obtain a nucleic acid molecule having a base sequence encoding the amino acid of the protein of the antibody, and the antibody is genetically engineered using such a nucleic acid molecule. It is also possible to produce.
- the H chain, L chain, or variable regions thereof in the genetic information of the antibody can be modified to improve the binding property and specificity of the antibody by referring to the information such as the CDR sequences.
- mammalian cells, insect cells, Escherichia coli, etc. into which a gene encoding the amino acid of the antibody of the antibody to be obtained is introduced are cultured, and the obtained culture supernatant is used by a conventional method.
- the antibody can be purified and obtained.
- the specific method is not limited to this, but the following methods are exemplified.
- a nucleic acid molecule encoding an H chain variable region is bound to a nucleic acid molecule encoding an H chain signal peptide and a nucleic acid molecule encoding an H chain constant region. It is produced by binding a nucleic acid molecule encoding an L-chain signal peptide to a nucleic acid molecule encoding an L-chain variable region and a nucleic acid component encoding an L-chain constant region.
- H-chain gene and L-chain gene into a vector suitable for expression in a selected host cell, for example, a cloning vector or an expression vector.
- the H-chain gene and the L-chain gene may be integrated into one vector or may be integrated into different vectors as long as both genes are expressed.
- the vector into which the H-chain gene and the L-chain gene are integrated is introduced into the host cell.
- the host cell include eukaryotic cells such as mammalian cells, insect cells, yeast cells, or plant cells, or bacterial cells.
- a method for introducing a gene into a host cell appropriately select from a chemical method such as calcium phosphate or lipofection method, a physical method such as electroporation method or particle gun method, or a method by infection with a virus or phage. Can be done.
- Host cells into which the H-chain gene and L-chain gene have been introduced can be used for culture without selection, and recombinant cells into which the gene has been introduced using properties such as drug resistance and nutritional demand can be used. It is also possible to selectively concentrate or use a cloned recombinant cell established from a single host cell into which a gene has been introduced for culture.
- Host cells into which the H-chain gene and L-chain gene have been introduced are cultured in an appropriate medium and culture conditions.
- the products of the H chain gene and the L chain gene expressed in the host cell are usually secreted into the medium as an antibody protein, and the produced antibody protein can be obtained by recovering the medium.
- the host cell may be destroyed and the antibody protein accumulated in the cell may be recovered if necessary, and the antibody protein may be recovered from the periplasmic fraction in the case of prokaryotic cells. You can choose.
- concentration by salt precipitation method, dialysis, ultrafiltration, etc., exchange of solvent, protein A, protein G, antigen, etc. are immobilized.
- Affinity chromatography and the like using the same carrier are generally used, but other methods such as ion exchange chromatography, hydrophobic chromatography, mixed mode chromatography and size exclusion chromatography can also be appropriately used for purification. All of the various techniques used in these procedures are well known to those of skill in the art.
- the gene encoding the heavy chain and / or light chain of the immunoglobulin is genetically modified to introduce a desired trait, or the structure of the variable region or CDR region of the heavy chain and / or light chain of the immunoglobulin is performed. It is possible to produce an antibody chimeric protein, a small molecule antibody, a scaffold antibody, or the like by using information by using a technique known to those skilled in the art. Further, for the purpose of improving the performance of the antibody and avoiding side effects, it is also possible to modify the structure of the constant region of the antibody or to modify the sugar chain portion as appropriate by a technique well known to those skilled in the art. It can be carried out.
- the antibody of the present invention can be used as a therapeutic agent, a prophylactic agent, or a diagnostic agent for a disease caused by an IGF-1 related condition or an action on an IGF-1 receptor.
- the therapeutic / preventive drug or the diagnostic drug will be collectively referred to as “drug” or “drug”.
- the IGF-1 related state or the disease to be treated or prevented with the anti-IGF-1 receptor agonist antibody includes muscular atrophy diseases (for example, disused muscular atrophy, sarcopenia, caquexia and the like). ), Short stature (eg Laron short stature, growth hormone resistant short stature, etc.), liver cirrhosis, liver fibrosis, diabetic nephropathy, chronic renal failure, aging, intrauterine fetal growth retardation (IUGR), nerves Diseases, strokes, spinal cord injuries, cardiovascular protection, diabetes, insulin resistance, metabolic syndrome, nephropathy, osteoporosis, cystic fibrosis, wound healing, muscular tonic dystrophy, AIDS muscle atrophy, fat relapse associated with HIV Distribution Syndrome, Burns, Crohn's Disease, Werner Syndrome, X-Chain Complex Immune Deficiency, Hearing, Neuropathic and Premature Infant Retinopathy, Turner Syndrome, Prader Willy Syndrome, Silver Russell Syndrome, Idiopathic Short Stature, Examples
- the antibodies of the present invention treat muscular atrophy diseases (eg, disused muscular atrophy, sarcopenia, cahexia, etc.) and / or short stature (eg, laron-type short stature, growth hormone-resistant short stature, etc.). It is preferably used as a drug or a prophylactic agent.
- the antibody of the present invention is excellent in that it does not cause fluctuations in blood glucose level by administration.
- Neuroblastoma is a disease to be treated, prevented, or diagnosed with an antibody drug, an antibody drug complex, or a diagnostic drug fused or linked with a part or all of this anti-IGF-1 receptor antibody as a component.
- the drug containing the antibody of the present invention may be formulated in the form of a pharmaceutical composition containing a pharmaceutically acceptable carrier and / or other additives in addition to the antibody of the present invention.
- Formulations using pharmaceutically acceptable carriers and / or other additives include, for example, University of the Sciences in Philadelphia, “Remington: The Science and Practice of Pharmacy, 20th EDITION”, Lippincot Williams & Wilkins, 2000. It can be carried out by the method described.
- a solution or lyophilizer prepared by dissolving, suspending, or emulsifying in a sterile aqueous or oily solution.
- a solvent or solution include distilled water for injection, physiological saline and the like as an aqueous solution, and in addition, an osmotic pressure regulator (for example, D-glucose, D-sorbitol, D-mannitol, sodium chloride).
- Etc. suitable solubilizing agents such as alcohols (eg ethanol), polyalcohols (eg propylene glycol, polyethylene glycol), nonionic surfactants (eg polysorbitol 80, polyoxyethylene hydrogenated castor oil 50). ) Etc.
- an oily liquid may be used as the solvent or the dissolution liquid, and examples of the oily liquid include sesame oil, soybean oil and the like, and benzyl benzoate, benzyl alcohol and the like may be used in combination as the dissolution aid.
- buffers eg, phosphate buffers, acetate buffers
- painkillers eg, benzalkonium chloride, prokine hydrochloride, etc.
- stabilizers eg, human serum albumin
- preservatives eg, ascorbic acid, erythorbic acid and salts thereof, etc.
- colorants eg, copper chlorophyll, ⁇ -carotene, red No. 2, blue No. 1, etc.
- preservatives eg, paraoxy.
- thickeners eg, hydroxypropyl cellulose, carboxymethyl cellulose and their salts, etc.
- stabilizers eg, human serum albumin, mannitol, sorbitol, etc.
- odor Additives of agents eg, menthol, citrus fragrance, etc.
- Another form is a drug for mucosal adaptation.
- the main purpose is to impart adsorptivity, retention, etc. to the mucous membrane, and as additives, a pressure-sensitive adhesive, a pressure-sensitive adhesive, a thickening agent, a thickening agent, etc. (for example, mutin, canten, etc.)
- a pressure-sensitive adhesive for example, mutin, canten, etc.
- Gelatin pectin, carrageenan, sodium alginate, locust bin gum, xanthan gum, tragant gum, gum arabic, chitosan, purulan, waxy starch, scralfate, cellulose, and derivatives thereof (eg, hydroxypropylmethylcellulose, polyglycerin fatty acid ester, acrylic acid (meth).
- Alkyl acrylate copolymer or a salt thereof, polyglycerin fatty acid ester, etc. may be contained.
- the form, solvent and additive of the therapeutic agent or preventive agent provided to the living body are limited to these. It is not a product, and any person in the art can select it as appropriate.
- the drug containing the antibody of the present invention may contain other existing drugs (active ingredients) in addition to the antibody of the present invention. Further, it may be fused or linked with other drugs such as antibody drug conjugates, bispecific antibodies and multispecific antibodies. Further, the drug containing the antibody of the present invention may be combined with other existing drugs to form a kit.
- anti-IGF-1 receptor agonist antibodies growth hormone or its analog, insulin or its analog, IGF-2 or its analog, anti-myostatin antibody, myostatin antagonist, anti-activin type IIB receptor antibody, activin IIB receptor Included are body antagonists, soluble activin type IIB receptors or analogs thereof, grelin or analogs thereof, follistatin or analogs thereof, beta 2 agonists, and selective androgen receptor modulators.
- the active ingredient combined with the anti-IGF-1 receptor antibody or the anti-IGF-1 receptor antibody is used together with the antibody drug or the antibody drug complex.
- the active ingredients contained include corticosteroids, anti-antibodies, ondancetron hydrochloride, granisetron hydrochloride, metoclopramide, donperidone, haloperidol, cyclidine, lorazepam, prochlorperazine, dexamethasone, levomepromazine, tropicetron, and cancer.
- Vaccines GM-CSF inhibitors, GM-CSF DNA vaccines, cell-based vaccines, dendritic cell vaccines, recombinant virus vaccines, heat shock protein (HSP) vaccines, allogeneic tumor vaccines, autologous tumor vaccines, analgesics, ibprofen, Naproxene, choline magnesium trisalicylate, oxycodon hydrochloride, anti-angiogenic drug, anti-thrombotic drug, anti-PD-1 antibody, nibolumab, pembrolizumab, anti-PD-L1 antibody, atezolizumab, anti-CTLA4 antibody, ipilimumab, anti-CD20 antibody, rituximab, anti HER2 antibody, trussumab, anti-CCR4 antibody, mogamurizumab, anti-VEGF antibody, bevasizumab, anti-VEGF receptor antibody, soluble VEGF receptor fragment, anti-TWEAK antibody, anti-TWEAK receptor antibody,
- the agent of the present invention can be administered parenterally for the purpose of improving symptoms.
- parenteral administration for example, it can be a nasal agent, and a liquid agent, a turbid agent, a solid preparation and the like can be selected.
- Another form of parenteral administration may be an injection, and the injection may be a subcutaneous injection, an intravenous injection, a drip injection, an intramuscular injection, an intraventricular injection, an intraperitoneal injection, or the like. Can be selected.
- other preparations used for parenteral administration include suppositories, sublingual agents, transdermal agents, transmucosal agents other than nasal agents, and the like. Further, it can be locally administered intravascularly by containing or applying it to a stent or an intravascular embolic agent.
- the dose of the therapeutic or prophylactic agent in the present invention varies depending on the age, sex, body weight, symptom, therapeutic effect, administration method, treatment time, type of active ingredient contained in the pharmaceutical composition, and the like of the patient.
- the main ingredient is in the range of 0.1 mg to 1 g, preferably 0.5 mg to 100 mg, once every 1 to 4 weeks, or 1 to 1 to 2 months.
- a dose and the number of doses may be sufficient, and a dose and the number of doses exceeding the above range may be required. be.
- Example 1 Design of humanized antibody of mouse antibody IGF11-16: -Selection of human framework IGF11-16, a mouse monoclonal antibody against the IGF-1 receptor, obtained by the hybridoma method of Kohler et al. (Nature, (1975), Vol.256, pp.495-497) (Patent Document 1). ) Complementarity determining region (CDR) amino acids in the heavy chain variable region (VH) and light chain variable region (VL) were transplanted into a template human antibody.
- CDR complementarity determining region
- an amino acid sequence having high homology to the VH and VL amino acid sequences (SEQ ID NO: 39 and SEQ ID NO: 41, respectively) of the mouse antibody IGF11-16 (mouse parent antibody) is used. From the germline of the human antibody having, VH-1-46 (SEQ ID NO: 95) and VH-1-e (SEQ ID NO: 96) as the heavy chain sequence, and JH4 (SEQ ID NO:) as the heavy chain J-segment.
- VK1-L5 SEQ ID NO: 98
- VK1-A20 SEQ ID NO: 99
- JK2 SEQ ID NO: 100
- Humanized antibodies were prepared by transplanting the necessary amino acid sequences from VH and VL of mouse antibodies IGF11-16 into the FRs of the above template human antibodies VH and VL.
- VH the CDR amino acid sequence of the template human antibody VH described above and several FR amino acids were replaced with the corresponding amino acid sequences in the VH of the mouse antibody IGF11-16 to humanize the mouse antibody IGF11-16.
- the amino acid sequence of the VH was designed, and the base sequence of the DNA encoding those amino acids was further designed.
- VL the CDR amino acid sequence of the template human antibody VL and several FR amino acids were replaced with the amino acid sequences in the VL of the mouse antibody IGF11-16, and the amino acid sequence of the humanized mouse antibody IGF11-16 was designed. Then, the base sequence of the DNA encoding those amino acids was designed.
- the composition of the heavy chain and light chain of the designed humanized antibody is shown in Table 2 below.
- a humanized heavy chain composed by connecting a designed humanized antibody heavy chain variable region and a heavy chain constant region, and a designed humanized antibody light chain variable region.
- VL22 is a light chain variable region and a human ⁇ chain constant region is linked thereto
- VH13_PS is a heavy chain variable region
- IgG4S228P heavy chain constant is used therein.
- a humanized antibody constructed in combination with a heavy chain in which regions are linked.
- Example 2 Preparation of humanized antibody: DNA encoding the heavy chain variable region of the designed humanized antibody and the heavy chain constant region of the human IgG4S228P mutant, which is a mutant stabilized by the human IgG4 subclass, were synthesized and integrated into the pcDNA3.4 system expression vector. Then, a plasmid expressing the humanized antibody heavy chain was used.
- DNA encoding the humanized antibody light chain region linked to the ⁇ chain constant region was synthesized and incorporated into a pcDNA3.4 system expression vector to express the humanized antibody light chain. It was made into a plasmid to be used.
- Various antibodies were expressed by mixing these humanized antibody heavy chain expression plasmids and humanized antibody light chain expression plasmids and introducing them into cells using ExpiCHO (registered trademark) Expression System (Thermo Fisher Scientific). ..
- ExpiCHO registered trademark
- a humanized antibody expressed by combining a heavy chain expression plasmid incorporating FW1_VH1 and a light chain expression plasmid incorporating FW1_VL1 was incorporated into a FW1_var1 antibody, and a heavy chain expression plasmid incorporating FW2_VH1 and FW2_VL2 were incorporated.
- the humanized antibody expressed in combination with the light chain expression plasmid was named FW2_var2 antibody, respectively.
- FW1_var9, FW1_var10, and FW1_var14 were similarly implemented and named.
- the humanized antibody was obtained by affinity purification of the culture supernatant of the cells into which the humanized antibody heavy chain and the humanized antibody light chain expression plasmid were introduced using a protein A column. Subsequent preparation of humanized antibody was performed according to the above method.
- PathHunter by (R) IGF-1 agonism To detect activation activity IGF-1 receptor designed humanized antibody, PathHunter (TM) IGF1R Functional using Assay (DiscoverX), activation of IGF-1 receptor signaling by the following steps was measured.
- Cells expressing the IGF-1 receptor were placed in a poly-D-lysine-coated or collagen-I-coated 96-well plate (Black / clear or White / clear) at 90 ⁇ L / well (2 ⁇ 10 4 cells / well). Or seeded at 5 ⁇ 10 3 cells / well) and incubated at 37 ° C. and 5% CO 2 conditions. The next day, each concentration of drug was added at 10 ⁇ L / well and incubated at 37 ° C. and 5% CO 2 conditions.
- the next day 30 ⁇ L of the culture supernatant was taken, 15 ⁇ L of the substrate solution was added, the reaction was carried out for 60 minutes, and the luminescence signal (RLU) was measured with a luminometer (Tristar, Berthold).
- the relative value of the humanized antibody was calculated with the value obtained by subtracting the value at the time of adding the antibody 0.1 nM from the fluorescence intensity due to the addition of the 12.5 nM antibody as the activation intensity and the value of the mouse parent antibody IGF11-16 as 1. ..
- A61, Q62, Q65, and G66 of the heavy chain CDR2 region which is a sequence portion different from that of the mouse, are replaced with N61, E62, K65, and S66, respectively, in mice.
- Amino acid-substituted humanized antibodies (FW1_var10_NEKS, FW1_var14_NEKS) made the same as the parent antibody were prepared, and the mouse parent antibodies IGF11-16 and FW1_var1 were used as comparison targets to compare the IGF-1 receptor activation ability in the same manner as described above. did.
- humanized antibodies in which FR1, FR2, and FR3 were replaced with mouse FRs were prepared.
- the mouse FR substitutes of the prepared humanized antibody are shown in Table 5.
- the IGF-1 receptor signaling activation of these substituents were evaluated by a system of previously described PathHunter (registered trademark).
- PathHunter registered trademark
- human chimeric IGF11-16 antibody (Chimera) which is a fusion of the variable region of mouse parent antibody IGF11-16 and the constant region of human IgG4 (S228P)
- S228P human chimeric IGF11-16 antibody
- S228P constant region of human IgG4
- the signal intensities at an antibody concentration of 16.7 nM were compared in the same manner as described above.
- the results are shown in Table 5.
- examples of nucleic acid base sequences corresponding to the amino acid sequences of SEQ ID NOs: 29, 31, 33, 35, and 37 are shown in SEQ ID NOs: 30, 32, 34, 36, and 38, respectively
- the substitute having the same signal intensity as human chimeric IGF11-16 (value within ⁇ 20%) is FW1_var9_mFR-H1, and the mouse heavy chain FR1 is important for maintaining the activity of the humanized antibody. I found out.
- proline at position 25 in the heavy chain FR1 region is important for maintaining activity.
- Subsequent heavy chains of humanized antibodies were all P (proline, Pro) substituted at position 25.
- Example 4 Identification of CDR region amino acids important for maintaining activity by alanine substitution: For the purpose of identifying the amino acids required to retain activity in the CDR regions, each amino acid was replaced with alanine in the mouse parent antibody IGF11-16, and the signal activation ability of the substituted product was determined by EC 50 value and E max value. The binding activity was evaluated by the antigen ELISA. EC 50 value: within 2 times and E max value: within ⁇ 20% were defined as equivalent activity as compared with the mouse parent antibody IGF11-16.
- IGF-1 receptor signaling activation ability was evaluated by a system of PathHunter (registered trademark) described in Example 3.
- the EC 50 value and E max were calculated using the analysis software GraphPad Prism.
- the binding activity was measured by the antigen ELISA in which the extracellular region of the recombinant IGF-1 receptor was immobilized as an antigen.
- human recombinant IGF-1R manufactured by R & D
- PBS phosphate buffered saline
- the prepared human recombinant IGF-1R solution was added to the solidified plate at 50 ⁇ L / well. The reaction was carried out overnight at 4 ° C.
- the reaction was carried out at room temperature for 45 minutes, washed three times with a washing solution, and then a substrate (pNPP (paranitrophenyl phosphate)) was added to initiate the reaction. After reacting at room temperature for 1 hour, the absorbances at 405 and 550 nm were measured, and the value of the difference between the absorbances of 405 nm and the absorbance of 550 nm was calculated. This value was used as the binding activity for analysis.
- pNPP paranitrophenyl phosphate
- Tables 7 and 8 show the prepared IGF11-16 antibody CDR substitutes and the measurement results of signal activation and binding activity. From the obtained results, in the CDR region, the amino acid moiety whose binding activity was reduced to about 10 to 20% by substitution with alanine, that is, tryptophan at position 32 of CDR-L1, tryptophan at position 33 of CDR-H1, and CDR- It has been identified that five amino acids, glutamic acid at position 50 of H2, asparagine at position 52 of CDR-H2 and arginine at position 102 of CDR-H3, are crucial for retention of activity.
- histidine at position 35 of CDR-H1, serine at position 54 of CDR-H2, asparagine at position 55 of CDR-H2, serine at position 56 of CDR-H2, asparagine at position 59 of CDR-H2, and CDR Since the activity of phenylalanine at position 64 of -H2 decreased due to Ala substitution, it is considered that it contributes to the retention of activity. On the other hand, of the 54 amino acid residues in the alanine-substituted CDR regions, 44 showed 80% or more of the binding activity even after the alanine substitution.
- Example 5 Design of humanized heavy chain variable region: Since it was found from the results of Example 3 that proline at the 25th position of the heavy chain is important for maintaining the activity, the design was performed with the 25th position of the heavy chain as P and the humanized heavy chain variable regions FW1_VH1 and FW2_VH1 as the basic skeleton. .. Since the amino acid substitution product was examined based on FR1 of FW1_VH1, the amino acid substitution of S16A was performed in order to make the FR1 portion of FW2-VH1 the same as FW1_FR1. The amino acid substitutions introduced for immunogenicity reduction was performed on the basis of Epibase (R) (Lonza, Inc.) immunogenic score analysis results. The designed heavy chain variable region list is shown in Table 9 below.
- Example 6 Design of humanized light chain variable region: The humanized light chain variable region was designed with FW1_VL1 and FW2_VL2 as the basic skeletons. Amino acid substitutions introduced for immunogenicity score reduction was carried out based on the result of the analysis of Epibase (R) (Lonza, Inc.). A list of designed light chain variable regions is shown in the table.
- Example 7 Humanized antibody design with deamidation risk amino acid substitution product: If deamidation occurs during the production of humanized antibodies, quality control becomes difficult. Therefore, it is necessary to replace the amino acid at risk of deamidation with another amino acid that does not affect the activity in advance. Sequences generally at risk of deamidation include NG, NT, NS, and NN. The NS sequence is present in the CDR-H2 region of the heavy chain of this humanized antibody. Therefore, amino acid substitution was performed in consideration of the risk that asparagine (N) at position 55 is deamidated and converted to aspartic acid (D). A list of replaced heavy chains is shown in Table 11. Further, examples of the nucleic acid base sequences corresponding to the amino acid sequences of SEQ ID NOs: 45, 51, and 57 are shown in SEQ ID NOs: 46, 52, and 58, respectively.
- Example 8 Selection of humanized antibody by IGF-1 receptor signal activating action: Humanized antibodies were evaluated based on the activating effect of the IGF-1 receptor, and humanized antibodies having the same activity as the mouse parent antibody IGF11-16 were selected.
- IGF-1 receptor of the anti IGF-1 receptor agonist antibodies was determined the activation of IGF-1 receptor signaling using PathHunter (TM) IGF1R Functional Assay (DiscoverX) ..
- Cells expressing the IGF-1 receptor were placed in a poly-D-lysine-coated or collagen-I-coated 96-well plate (Black / clear or White / clear) at 90 ⁇ L / well (2 ⁇ 10 4 cells / well). Or seeded at 5 ⁇ 10 3 cells / well) and incubated at 37 ° C. and 5% CO 2 conditions. The next day, each concentration of drug was added at 10 ⁇ L / well and incubated at 37 ° C. and 5% CO 2 conditions. The next day, 30 ⁇ L of the culture supernatant was taken, 15 ⁇ L of the substrate solution was added, the reaction was carried out for 60 minutes, and the luminescence signal (RLU) was measured with a luminometer (Tristar, Berthold).
- RLU luminescence signal
- the humanized antibody confirmed to have the same activity as the mouse parent antibody IGF11-16 (EC 50 value: within 2 times, E max value: within ⁇ 20% compared with the mouse parent antibody IGF11-16) is shown in the table. Shown in 12.
- Example 9 Selection of humanized antibody by human myoblast proliferation activity: Humanized antibodies were evaluated based on human myoblast proliferation activity, and humanized antibodies having activity equivalent to that of mouse parent antibody IGF11-16 were selected.
- the 96-well plate incubated for 4 days was allowed to stand at room temperature for 30 minutes or more after removing the supernatant so that the culture solution became 50 ⁇ L / well.
- the emission signal was measured with a luminometer (Tristar, Berthold).
- Table 13 shows the humanized antibodies confirmed to have the same activity as the mouse parent antibody IGF11-16 (EC 50 value: 10 times or less, E max : 90% or more as compared with the mouse parent antibody IGF11-16). show.
- the graphs of the measurement results are shown in FIGS. 1A to 1F.
- Example 10 Evaluation of immunogenicity: In order to analyze the immunogenicity of the humanized antibody, using Epibase (TM) in Silico of Lonza, it was calculated immunogenicity score. Lonza's Epibase (TM) in Silico platform, using structural characteristics of the HLA class II receptors previously with binding affinity of the peptide and HLA class II receptors 10-mer which is determined experimentally, the antibody It is an immunogenicity prediction method that predicts potential peptide / HLA binding, which is a condition necessary for activation of T cells present in the contained amino acid sequence, and calculates it as an immunogenicity score.
- TM Epibase
- siico platform using structural characteristics of the HLA class II receptors previously with binding affinity of the peptide and HLA class II receptors 10-mer which is determined experimentally, the antibody It is an immunogenicity prediction method that predicts potential peptide / HLA binding, which is a condition necessary for activation of T cells present in the contained amino acid sequence, and calculates it as an immunogenicity score.
- HLA class II allotypes 43 types of DRB1, 8 types of DRB3 / 4/5, 22 types of DQ, 12 types of DP
- the immunogenicity score was scored by taking into account the frequency of appearance in addition to the binding affinity of allotypes.
- Example 11 Evaluation of binding activity to mammalian IGF-1 receptor: Anti-IGF against IGF-1 receptors in humans (SEQ ID NO: 71), crab monkeys (SEQ ID NO: 73), rabbits (SEQ ID NO: 75), guinea pigs (SEQ ID NO: 77), rats (SEQ ID NO: 79) and mice (SEQ ID NO: 81). In order to examine the binding activity of the -1 receptor agonist antibody, Cell-based ELISA was performed using cells expressing various IGF-1 receptors.
- HEK293T cells After lipofection was added to HEK293T cells were incubated over night in 96 well plates at 4 ⁇ 10 4 cells / well (poly -D- lysine-coated), 10% buffered formalin (Mildform (registered trademark) 10 nm, Wako) The one that was fixed using and blocked with a phosphate buffer solution containing 3% BSA was used for ELISA.
- ELISA was prepared by adding 100 ⁇ L of each humanized antibody solution prepared to 5 nM with 1% BSA / 1% FBS / PBS to each well and reacting at 37 ° C. for about 1 hour. It was washed 3 times with a washing solution. 100 ⁇ L of anti-human IgG antibody HRP conjugated solution prepared at each concentration with 1% BSA / 1% FBS / PBS was added to each well, reacted at 37 ° C. for about 1 hour, and washed 3 times with a washing solution. .. 100 ⁇ L of substrate (TMB) was added to each well to initiate the reaction.
- TMB substrate
- FIG. 2 shows the results of reactivity of humans, guinea pigs, cynomolgus monkeys, and rabbits with each IGF-R.
- the humanized antibodies hIGF13_PS and hIGF25_PS increased the binding activity of human, guinea pig, cynomolgus monkey, and rabbit IGF-1 receptors by about twice as much as those of Mock cells, and the human mouse chimera. It was as reactive as antibody IGF11-16.
- the binding activity to cells expressing the IGF-1 receptor in rats and mice was similar to that of Mock cells.
- Binding affinity for IGF-1 receptor by surface plasmon resonance method To examine the binding properties (binding rate and dissociation rate) of the drug to the IGF-1 receptor, it was measured by the surface plasmon resonance (SPR) method.
- the measurement system used was the BIACORE T200 system.
- Anti-histidine-tagged monoclonal antibody was applied to all flow cells of the sensor chip CM3 (BR-1005-36, GE) with AmineCouplingKit (BR-1000-50, GE) and HisCaptureKit (28-9950-56, GE). , Approximately 3000 RU fixed and used.
- HBS-EP + (BR-1006-69, GE) was used as the running buffer.
- IGF-1R-His a recombinant human IGF-1 receptor histidine tag (305-GR-050, R & D SYSTEMS, hereinafter IGF-1R-His) was captured and used in the measurement system.
- Analite used each concentration of drug.
- a flow cell that did not capture IGF-1R-His was used as a ligand negative control.
- PBS PBS pH 7.4 (1x), # 10010049, Gibco
- the measurement temperature of the measurement system was set to 40 ° C.
- the anti-histidine-tagged monoclonal antibody of Frocel (2 and 4) was reacted with IGF-1R-His ( ⁇ 2 ⁇ 10 -8 M) so as to be 100 RU or less.
- IGF-1R-His ⁇ 2 ⁇ 10 -8 M
- 10 nM purified mice IgG2a, ⁇ , isotype Ctrl, Clone: MG2a-53 (401502, BioLegend, hereinafter ctrl IgG2a) were reacted for 1 minute, and HBS-EP + was allowed to flow for 10 minutes or longer.
- Analite was serially diluted with HBS-EP + (0.5-8 ⁇ 10 -10 M) and reacted with all flow cells.
- Example 13 In vivo hypoglycemic action (hypoglycemic action in guinea pigs): In order to confirm the presence or absence of the in vivo hypoglycemic effect of the anti-IGF-1 receptor agonist antibody, hIGF13_PS and hIGF25_PS were administered once to guinea pigs, and the blood glucose level was measured over time to determine the hypoglycemic effect. The presence or absence was examined. The hypoglycemic action is an action of lowering the blood glucose level to 50 mg / dL or less or causing hypoglycemic symptoms.
- the guinea pig was fasted for 12 hours, and each humanized antibody: hIGF13_PS and hIGF25_PS was intravenously administered at 10 mg / kg in a single dose.
- Guinea pigs were fasted until 24 hours after dosing.
- Wakeful guinea pigs were collected before administration (0 hours), 1, 2, 4, 8, 24, 48, 72, and 144 hours after administration, and used with a glutest sensor (Sanwa Chemical Laboratory). The blood glucose level was measured. The results are shown in FIGS. 3A and 3B.
- each humanized antibody does not have a remarkable hypoglycemic effect like IGF-1, and does not affect the blood glucose level. Therefore, as a drug for overcoming hypoglycemia, which is a side effect of IGF-1. The possibility of was shown.
- Example 14 Blood kinetics of humanized antibody in guinea pigs: The guinea pigs were fasted for 12 hours and a single intravenous dose of 1 and 10 mg / kg of humanized antibodies hIGF13_PS and hIGF25_PS or IGF11-16 (mouse parent antibody) was administered. Guinea pigs were fasted until 24 hours after dosing and re-fed 24 hours later. Awake guinea pigs were collected before administration (0 hours), 2, 4, 8, 24, 48, 72, 96, 120, and 144 hours after administration, and the plasma humanized antibody concentration was measured by ELISA. ..
- the antibody having a known concentration administered to the guinea pig was serially diluted with guinea pig plasma to obtain a standard substance.
- the standard substance and plasma were diluted 10 to 1000 times and measured.
- a 0.5 ⁇ g / mL PBS solution of recombinant IGF-1R was added to a 96-well plate (MaxiSorp (NUNC)) and fixed at 4 ° C. overnight. Further blocking was performed with 3% BSA / PBS to prepare a recombinant IGF-1R fixation plate.
- guinea pig plasma to which no antibody was administered was used, and the administered antibody was serially diluted to obtain a standard substance. Plasma and standard material were diluted 10-fold and added to recombinant IGF-1R fixation plates at 50 ⁇ L / well.
- the reaction was carried out at room temperature for 1 hour and 30 minutes, and then a washing operation was carried out with PBS-T (PBS, 0.025% Tween 20). Then, a solution of alkaline phosphatase-labeled anti-human IgG (H + L) polyclonal antibody (Southern Biotechnology Associates, Cat # 2087-04) diluted 2000 times with 3% BSA / PBS was added at 50 ⁇ L / well, and the mixture was added at room temperature for 1 hour. It was reacted.
- PBS-T PBS, 0.025% Tween 20
- H + L alkaline phosphatase-labeled anti-human IgG polyclonal antibody
- the results are shown in Fig. 4.
- the plasma humanized antibody concentration increased depending on the dose, and even in the low dose group, the plasma humanized antibody concentration up to 144 hours after administration was maintained at about 50% or more as compared with 24 hours after administration.
- the blood kinetics of the humanized antibody was shown to be superior in sustainability as compared with the mouse parent antibody IGF11-16.
- Example 15 Muscle mass increasing action of humanized antibody in normal guinea pigs: A single dose of hIGF13_PS was intravenously administered to normal guinea pigs, and the muscle mass was measured 2 weeks later. did.
- hIGF13_PS and mouse parent antibody IGF11-16 was intravenously administered to normal guinea pigs at 0.1 mg / kg.
- human IGF-I (mecasermin) was subcutaneously implanted using an osmotic pump (Arzet) and continuously administered at 1 mg / kg / day.
- osmotic pump As a control, only the solvent was administered intravenously.
- the guinea pig was exsanguinated under anesthesia, the extensor digitorum longus muscle was removed, and the muscle mass was measured.
- the results are shown in Fig. 5.
- the drug efficacy was similar to that of the group in which human IGF-I was continuously administered at 1 mg / kg / day and the drug efficacy intensity in which the mouse parent antibody IGF11-16 was intravenously administered.
- hIGF13_PS can be expected to have the same efficacy as the continuous administration of human IGF-1 for 2 weeks by a single dose.
- Example 16 Growth plate cartilage elongation action in pituitary excised guinea pigs of humanized antibody: The epiphyseal line thickness of the proximal tibia was evaluated using a guinea pig pituitary excision (HPX) model as an evaluation of the growth plate cartilage proliferation effect of hIGF13_PS.
- HPX guinea pig pituitary gland removal
- HIGF13_PS was subcutaneously administered once to pituitary excised guinea pigs at 0.3 mg / kg and 1.0 mg / kg, and the right lower limb was collected 2 weeks later.
- a tissue specimen of the growth plate cartilage in the proximal part of the tibia was prepared, and the thickness of the growth plate cartilage (epiphyseal plate thickness) was measured by Truisin Blue.
- the IGF-1 (mecasermin) preparation was continuously subcutaneously administered at 1 mg / kg / day with an osmotic pump, and the GH (somatropin) preparation was subcutaneously administered at 1 mg / kg / day once daily.
- the hIGF13_PS antibody has an effect of recovering the obstruction of the epiphyseal line due to the decrease in IGF-1 concentration due to the pituitary excision (HPX) treatment by activating the signal mediated by IGF-1R.
- HPX pituitary excision
- Example 17 Hypoglycemic effect of humanized antibody in cynomolgus monkey: In order to confirm the presence or absence of the hypoglycemic effect of the anti-IGF-1 receptor agonist antibody in cynomolgus monkeys, hIGF13_PS was administered once to cynomolgus monkeys, and the blood glucose level was measured sequentially to measure IGF-1 (1 mg / kg). ) was compared with the hypoglycemic effect of a single dose.
- the hypoglycemic action is an action that lowers the blood glucose to less than 50% or causes hypoglycemic symptoms as compared with the solvent-administered group.
- Humanized antibody was administered to cynomolgus monkeys at 10 mg / kg once intravenously or subcutaneously. Blood was collected before (0 hours), 5 minutes, 30 minutes, 1, 2, 4, 8, and 24 hours after administration, and the blood glucose level was measured using Medisafe Fit (Terumo Corporation).
- Example 18 Blood kinetics of humanized antibody in cynomolgus monkeys: The humanized antibody hIGF13_PS was administered once intravenously or subcutaneously to cynomolgus monkeys at 1 and 10 mg / kg. Blood was collected before administration (0 hours), 2, 4, 8, 24, 48, 72, and 144 hours after administration, and the concentration of humanized antibody in plasma was measured by ELISA.
- the calibration curve for quantification was a standard substance obtained by serially diluting an antibody of known concentration administered to monkeys with monkey plasma. The standard substance and plasma were diluted 10 to 1000 times and measured.
- a 0.5 ⁇ g / mL PBS solution of recombinant IGF-1R was added to a 96-well plate (MaxiSorp (NUNC)) and fixed at 4 ° C. overnight. Further blocking was performed with 3% BSA / PBS to prepare a recombinant IGF-1R fixation plate.
- monkey plasma to which no antibody was administered was used, and the administered antibody was serially diluted to obtain a standard substance. Plasma and standard material were diluted 10-fold and added to recombinant IGF-1R fixation plates at 50 ⁇ L / well. The reaction was carried out at room temperature for 1 hour and 30 minutes, and then a washing operation was carried out with PBS-T (PBS, 0.025% Tween 20).
- the absorbance at 405 nm and 550 nm was measured with a plate reader, and the value of the difference between the absorbances of 405 nm and 550 nm was calculated.
- a calibration curve was drawn with the antibody concentration as the standard substance, and the antibody concentration in plasma was calculated.
- Muscle mass increasing action of humanized antibody in cynomolgus monkey Two cynomolgus monkeys were intravenously administered with hIGF13_PS at 1 mg / kg. Muscle mass was measured by the DXA (Dual Energy X-ray Absorptiomyomy) method before administration and 3 to 4 weeks after administration.
- DXA Direct Energy X-ray Absorptiomyomy
- ketamine hydrochloride (Arevipharma GmbH, 50 mg / mL, 0.2 mL / kg) and an aqueous solution of medetomidine hydrochloride (domitol, Orion Corporation, 1 mg / mL, 0.08 mL / kg) were used.
- General anesthesia is performed by intramuscular administration (buttock), and using a dual energy X-ray absorption measuring device (Discovery-A, HOLOGIC), fat mass (Fat Mass, g) and non-fat mass (Lean Body Mass, g) are used.
- Bone mass Bone Mineral Content (BMC), g) was measured, and non-fat mass was analyzed as muscle mass.
- BMC bone mineral content
- Lean + BMC g
- muscle mass g was calculated, and compared with the muscle mass before administration.
- hIGF13_PS was subcutaneously administered to 2 cynomolgus monkeys at 10 mg / kg. Muscle mass was measured by the DXA (Dual Energy X-ray Absorptiomyomy) method before administration and 3 to 4 weeks after administration.
- DXA Direct Energy X-ray Absorptiomyomy
- ketamine hydrochloride (Arevipharma GmbH, 50 mg / mL, 0.2 mL / kg) and an aqueous solution of medetomidine hydrochloride (domitol, Orion Corporation, 1 mg / mL, 0.08 mL / kg) were used.
- General anesthesia is performed by intramuscular administration (buttock), and using a dual energy X-ray absorption measuring device (Discovery-A, HOLOGIC), fat mass (Fat Mass, g) and non-fat mass (Lean Body Mass, g) are used.
- Bone mass Bone Mineral Content (BMC), g) was measured, and non-fat mass was analyzed as muscle mass.
- BMC bone mineral content
- Lean + BMC g
- Example 20 Effect of IGF11-16 on HepG2 cell proliferation The concentration-dependent effect of the mouse parent antibody IGF11-16 on HepG2 cell proliferation was evaluated by a cell survival assay.
- HepG2 cell lines were suspended in DMEM (Gibco, 11995) with 1% FBS and seeded in collagen-I coated 96-well plates (Corning, 356650) at 0.25 ⁇ 10 4 cells / well. The next day, BSA / PBS, IGF-1 (mecasermin), control mouse IgG1 antibody (mIgG1), IGF11-16 antibody, and Sixtumumab (IGF-1 receptor antagonist antibody) were diluted from 50 nM at a ratio of 1/10. And added.
- the mouse parent antibody IGF11-16 showed an inhibitory effect on HepG2 cell proliferation. From this result, it was considered that IGF11-16 could exhibit an antagonistic effect on at least certain cancer cells.
- Example 21 Effect of IGF11-16 on the proliferative activity of human breast cancer cell line (MCF7) by IGF-1 to evaluate the effect of IGF11-16 on the proliferative activity of human breast cancer cell line (MCF7) by IGF-1, 50 nM The concentration-dependent proliferative activity of hIGF-1 (mechaselmin) under the condition of coexistence of IGF11-16 was measured by the amount of intracellular ATP 2 days after the addition.
- Human breast cancer cell lines were cultured in DMEM / F12 medium containing 10% FBS. The next day, using DMEM / F12 medium containing 10% FBS, seeded in 96-well plates (Collagen-type I coated) at 0.1 mL / well (2.5 ⁇ 10 3 cells / well) at 37 ° C. Incubated under 5% CO 2 conditions. The day after cell seeding, the medium was replaced with DMEM / F12 medium containing 1% BSA, and the cells were incubated at 37 ° C. and 5% CO 2 for about 8 hours.
- the mouse parent antibody IGF11-16 has an inhibitory effect on reducing the maximum activity of the human breast cancer cell line (MCF7) by IGF-1. From this result, it was considered that IGF11-16 has the action of an allosteric antagonist.
- the present invention provides an anti-IGF-1 receptor humanized antibody that specifically binds to the IGF-1 receptor in vertebrates and does not lower blood glucose levels while increasing muscle mass via the IGF-1 receptor. It can be used for the treatment, prevention, or diagnosis of diseases associated with the IGF-1 receptor. The present invention can also be used for the treatment, prevention, or diagnosis of diseases associated with cell overgrowth or activation by suppressing the excessive signal of the IGF-1 receptor, and is industrially available. The value is extremely high.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
IGF-1は、インスリン様成長因子であり、下垂体から分泌される成長ホルモン(GH)によるGH受容体の活性化を介して、主に肝臓から分泌され、IGF-1受容体に作用することにより、各種臓器で種々の生理機能を発現する。このことからIGF-1は、種々の疾患への治療が期待される。IGF-1は、プロインスリンのアミノ酸配列と比較して、約40%と高い相同性を有することから、インスリン受容体にも結合して、インスリン様の作用を発現することがある。また、IGF-1受容体は、インスリン受容体のアミノ酸配列と比較して、約60%と高い相同性を有することから、両受容体はヘテロ二量体を形成することによっても、生理作用を発揮する。なお、インスリンは、インスリン受容体に作用することにより、強力な血糖低下作用を発現することから、血糖降下薬として治療に用いられている。
IGF-1受容体はα鎖及びβ鎖で構成され、L1、CR、L2、Fn1、Fn2、及びFn3の6つの細胞外ドメイン、膜貫通ドメイン、及び細胞内ドメインを含む膜貫通タンパク質である。IGF-1受容体の細胞内ドメインは、チロシンキナーゼを有する。細胞外ドメインは、IGF-1がIGF-1受容体に結合した時の当該受容体の立体構造の変化に伴う、細胞内のチロシンキナーゼの活性化に関与する。IGF-1受容体は、ホモ二量体複合体(ホモ型)を形成して、IGF-1が結合すると、受容体キナーゼを活性化することにより信号を送る。また、インスリン受容体とのヘテロ二量体複合体(ヘテロ型)を形成して、インスリン又はIGF-1が結合すると、受容体キナーゼを活性化することにより信号を送る。
IGF-1は、身長や体重増加等の成長促進作用、及び、糖代謝促進や血糖低下作用等のインスリン様代謝作用が明らかにされている。ヒト組換えIGF-1であるメカセルミンは、インスリン受容体異常症の高血糖、高インスリン血症、黒色表皮腫及び多毛といった症状を改善することが認められている。また、成長ホルモン抵抗性低身長症の成長障害を改善することが認められている(非特許文献1)。
IGF-1は、成長促進の主要な因子である(非特許文献2、非特許文献3)。実際に、ヒト組換えIGF-1であるメカセルミンは、低身長症の治療薬として臨床で用いられている。また、IGF-1はヒト軟骨細胞のDNA合成能を亢進させることが知られている。また、IGF-1の投与は、下垂体摘出ラットの体重を増加させ、大腿骨骨長を伸長させる。
IGF-1を介した細胞増殖活性の亢進は、IGF-1受容体の持続的な活性化が必要である。IGF-1受容体を過剰発現させた動物では筋肉量が増加している。また、IGF-1/IGFBP3の持続投与は、大腿骨近位部骨折患者の握力を亢進させ、介助なしでの座位からの立ち上がり能力を改善させる。高齢のヒト及びマウスの筋肉中のIGF-1濃度は、若齢と比較して低下することが知られているが、IGF-1を筋組織特異的に強制発現させた高齢のマウスでは、野生型マウスと比較して、筋肉量が改善した(非特許文献4)。
グレリン受容体の作動薬であるアナモレリンは、廃用性筋萎縮症であるカケキシアの臨床試験において、除脂肪量を増加させた。一方、副作用として、吐き気及び血糖値の上昇が認められる。ミオスタチンは、アクチビン受容体II(ActRII)に作用して、Akt/mTORを阻害する、骨格筋形成の負の制御因子である。抗ミオスタチン抗体であるLY2495655は、全人工股関節置換術を実施した患者及び高齢者の筋肉量を増加させる。また、抗ActRII抗体であるビマグルマブは、神経筋疾患患者の筋肉量を増加させる。しかし、骨格筋の形成を促進させ、治療のために使用できる薬は現在のところ存在しない。
IGF-1のインスリン様作用として、血糖低下作用が知られている。IGF-1は、ラット筋肉由来細胞においてグルコース取込み作用を亢進させる。また、IGF-1の投与は、ラットの血糖値を低下させる。IGF-1による血糖低下作用は、臨床上の副作用として低血糖症状を惹起させることが報告されている。更に、IGF-1は、ヒトへの投与により低血糖症状を起こすことから、治療開始時は、低用量から順次適当量を投与し、投与後の血糖値等を含む各種臨床所見の観察が必要となる。
IGF-1の血中半減期は、短いため治療では頻回投与が必要となる。実際に、ヒト組換えIGF-1であるメカセルミンは、血中半減期が約11時間から16時間であり、低身長症の治療では1日1回から2回の投与が必要である。血中のIGF-1の約70から80%はIGFBP3と結合している。IGF-1の遊離体が生理活性を示す。IGFBP3との結合は、IGF-1の血中半減期を約10時間から16時間に維持している。IGF-1とIGFBP3の配合剤であるIPLEXは、血中半減期が約21時間から26時間とIGF-1と比較して長く、1日1回の投与を可能にした薬剤である。しかし、IPLEXは市場から撤退している。IGF-1の動態を改善させたPEG化IGF-1も開発が試みられたが、治療に用いられている薬剤は存在しない。
IGF-1は多種の臓器に作用し、その生理機能は多岐にわたることが知られている。例えば、IGF-1は、中枢神経系において、IGF-1受容体の活性化を介して、ミトコンドリアの保護及び抗酸化作用による神経保護作用があることが報告されている。IGF-1は、傷害後の神経突起の形成を促進させる。また、IGF-1は、肝硬変の治療に有用であると考えられている。肝硬変は、肝障害又は慢性肝疾患から病態進展したものであり、肝臓の線維化を伴う疾患である。肝硬変モデル動物において、IGF-1の投与は、肝臓の線維化を抑制した。更に、IGF-1は、腎臓の発達、機能にも関与することが知られている。腎臓のメサンギウム細胞において、IGF-1は、糖毒性による酸化ストレス及びアポトーシスに対して保護作用がある。IGF-1は、腎症の治療薬として期待される。
抗体製剤は、一般的に半減期が長く、月に1回から2回の投与で有効性を示す。抗IGF-1受容体アゴニスト抗体は、インビトロ(in vitro)における短時間処理での受容体活性化作用がいくつか報告されている。例えば、抗体3B7及び抗体2D1は、インビトロにおいて5時間培養した組換えIGF-1受容体発現細胞のDNA合成を促進した(非特許文献5)。また、がん細胞株の増殖抑制活性を有する抗IGF-1受容体アンタゴニスト抗体11A1、11A4、11A11、及び24-57は、インビトロにおいて極めて微弱であるがIGF-1受容体のチロシンのリン酸化を亢進した(非特許文献6)。また、抗体16-13、17-69、24-57、24-60、及び24-31は、インビトロにおいて短時間における細胞のDNA合成、及びグルコース取込みの亢進作用を有することが示されており、これらの抗体は血糖低下作用を有する可能性がある(非特許文献7)。
IGF-1受容体に結合する抗体は、IGF-1とIGF-1受容体との結合を阻害するアンタゴニスト作用を利用して、悪性腫瘍等の治療への応用が試みられている。しかしながら、既存の抗IGF-1受容体アンタゴニスト抗体は単独治療において高血糖等の副作用が多いだけでなく(非特許文献9)、他の抗癌剤との併用により高血糖の発現率が上昇することから(非特許文献10)、治療への適用は限定的なものになるものと考えられている。近年、甲状腺機能亢進症における眼症への適応でテプロツムマブ(Teprotumumab)が承認された(非特許文献11)。
[1]マウス親抗体IGF11-16に由来する重鎖及び軽鎖の各相補性決定領域(CDR)と、ヒト抗体に由来する重鎖及び軽鎖の各フレームワーク領域(FR)とを含むと共に、少なくとも1つのCDRが、マウス親抗体IGF11-16の対応するCDRに対して、少なくとも1箇所のアミノ酸残基の置換を含む、抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[2]重鎖可変領域のフレームワーク領域1(FR-H1)の25位のアミノ酸残基がプロリンである、項[1]に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[3]重鎖可変領域のCDR-1(CDR-H1)配列として、配列番号1のアミノ酸配列、又は、配列番号1の何れか1箇所のアミノ酸残基が置換されたアミノ酸配列、
重鎖可変領域のCDR-2(CDR-H2)配列として、配列番号3若しくは配列番号5のアミノ酸配列、又は、配列番号3若しくは配列番号5の何れか1箇所、2箇所、若しくは3箇所のアミノ酸残基が置換されたアミノ酸配列、
重鎖可変領域のCDR-3(CDR-H3)配列として、配列番号7のアミノ酸配列、又は、配列番号7の何れか1箇所若しくは2箇所のアミノ酸残基が置換されたアミノ酸配列、
軽鎖可変領域のCDR-1(CDR-L1)配列として、配列番号9のアミノ酸配列、又は、配列番号9の何れか1箇所若しくは2箇所のアミノ酸残基が置換されたアミノ酸配列、
軽鎖可変領域のCDR-2(CDR-L2)配列として、配列番号11のアミノ酸配列、又は、配列番号11の何れか1箇所のアミノ酸残基が置換されたアミノ酸配列、
軽鎖可変領域のCDR-3(CDR-L3)配列として、配列番号13のアミノ酸配列、又は、配列番号13の何れか1箇所若しくは2箇所のアミノ酸残基が置換されたアミノ酸配列
を含む、項[1]又は[2]に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[4]重鎖可変領域のCDR-1(CDR-H1)配列として、配列番号1と80%以上の相同性を有するアミノ酸配列、
重鎖可変領域のCDR-2(CDR-H2)配列として、配列番号3又は配列番号5と82%以上の相同性を有するアミノ酸配列、
重鎖可変領域のCDR-3(CDR-H3)配列として、配列番号7と75%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-1(CDR-L1)配列として、配列番号9と81%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-2(CDR-L2)配列として、配列番号11と85%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-3(CDR-L3)配列として、配列番号13と77%以上の相同性を有するアミノ酸配列
を含む、項[1]又は[2]に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[5]重鎖可変領域のCDR-1(CDR-H1)配列として、配列番号1の3位のTrpが維持され、又は、類似のアミノ酸残基に置換されたアミノ酸配列であって、当該3位のアミノ酸残基以外の何れか1箇所のアミノ酸残基が置換され、又は、配列番号1と80%以上の相同性を有するアミノ酸配列、
重鎖可変領域のCDR-2(CDR-H2)配列として、
配列番号3の1位のGlu及び3位のAsnが各々維持され、又は、類似のアミノ酸残基に置換されると共に、6位のAsnが維持され、又は、Ser若しくはGlnに置換されたアミノ酸配列であって、当該1位、3位、及び6位のアミノ酸残基以外の何れか1箇所、2箇所、若しくは3箇所のアミノ酸残基が置換され、又は、配列番号3と82%以上の相同性を有するアミノ酸配列、或いは、
配列番号5の1位のGlu及び3位のAsnが各々維持され、又は、類似のアミノ酸残基に置換されると共に、6位のSerが維持され、又は、Asn若しくはGlnに置換されたアミノ酸配列であって、当該1位、3位、及び6位のアミノ酸残基以外の何れか1箇所、2箇所、若しくは3箇所のアミノ酸残基が置換され、又は、配列番号5と82%以上の相同性を有するアミノ酸配列、
重鎖可変領域のCDR-3(CDR-H3)配列として、配列番号7の4位のArgが維持され、又は、類似のアミノ酸残基に置換されたアミノ酸配列であって、当該4位のアミノ酸残基以外の何れか1箇所若しくは2箇所のアミノ酸残基が置換され、又は、配列番号7と75%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-1(CDR-L1)配列として、配列番号9の9位のTrpが維持され、又は、類似のアミノ酸残基に置換されたアミノ酸配列であって、当該9位のアミノ酸残基以外の何れか1箇所若しくは2箇所のアミノ酸残基が置換され、又は、配列番号9と81%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-2(CDR-L2)配列として、配列番号11の何れか1箇所のアミノ酸残基が置換され、又は、配列番号11と85%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-3(CDR-L3)配列として、配列番号13の何れか1箇所若しくは2箇所のアミノ酸残基が置換され、又は、配列番号13と77%以上の相同性を有するアミノ酸配列
を含む、項[1]又は[2]に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[6]配列番号71のアミノ酸配列を有するヒトIGF-1受容体の細胞外ドメインに特異的に結合する、請求項1~5の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[7]重鎖可変領域として、配列番号43、47、49、53、55、若しくは59のアミノ酸配列、配列番号43、47、49、53、55、若しくは59のアミノ酸配列において1若しくは数箇所のアミノ酸残基が置換、欠失、若しくは付加されたアミノ酸配列、又は、配列番号43、47、49、53、55、若しくは59と90%以上の相同性を有するアミノ酸配列、及び、
軽鎖可変領域として、配列番号65、67、若しくは69のアミノ酸配列、配列番号65、67、若しくは69のアミノ酸配列において1若しくは数箇所のアミノ酸残基が置換、欠失、若しくは付加されたアミノ酸配列、又は、配列番号65、67、若しくは69と90%以上の相同性を有するアミノ酸配列
を含む、項[1]~[6]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[8]重鎖及び/又は軽鎖の定常領域として、ヒト免疫グロブリンの何れかのクラスの重鎖及び/又は軽鎖の定常領域を含む、項[1]~[7]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[9]重鎖定常領域が、ヒトIgG4クラスの重鎖定常領域又はその1~10箇所のアミノ酸が置換された定常領域である、項[1]~[8]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[10]重鎖定常領域が、ヒトIgG1クラスの重鎖定常領域又はその1~10箇所のアミノ酸が置換された定常領域である、項[1]~[8]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[11]IGF-1受容体に対して平衡解離定数(KD)1×10-7M以下の親和性で結合する、項[1]~[10]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[12]IGF-1受容体シグナル活性化能を有する、項[1]~[11]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[13]筋芽細胞増殖試験において、増殖活性を有する、項[1]~[12]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[14]BIACOREによる組換え可溶性IGF-1受容体への結合性試験において、マウス親抗体IGF11-16と同等以上の結合親和性を有する、項[1]~[13]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[15]正常哺乳動物において、低血糖症状を誘導せず、筋量増加作用を誘導しうる、項[1]~[14]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[16]下垂体摘出モデル動物において、低血糖症状を誘導せず、成長板軟骨伸長作用を誘導しうる、項[1]~[15]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[17]脊椎動物の筋肉量及び/又は体長の増加を誘導する用量において当該脊椎動物に投与された場合に、当該脊椎動物の血糖値を低下させない、項[1]~[16]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[18]脊椎動物の筋肉量及び/又は体長の増加を誘導する有効用量に対して10倍以上の血中曝露量においても、当該脊椎動物の血糖値を低下させない、項[1]~[16]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[19]IGF-1受容体シグナル活性化抑制能を有する、項[1]~[18]の何れか一項に記載のヒト化抗体若しくはその断片、又はそれらの誘導体。
[20]筋芽細胞増殖試験において、IGF-1受容体を活性化しうるリガンドであるIGF-1、IGF-2、及びインスリンの少なくとも一つの増殖活性を抑制する、項[1]~[18]の何れか一項に記載のヒト化抗体若しくはその断片、又はそれらの誘導体。
[21]がん細胞増殖試験において、細胞増殖を抑制する活性を有する、項[1]~[20]の何れか一項に記載のヒト化抗体若しくはその断片、又はそれらの誘導体。
[22]抗IGF-I受容体抗体もしくはその断片、又はそれらの誘導体が、1)~4)の少なくとも一つの特徴を有する、項[1]~[21]のいずれか一項に記載の抗IGF-I受容体抗体もしくはその断片、又はそれらの誘導体。
1)IGF-I受容体活性化リガンドによる脊椎動物由来細胞の増殖を阻害する。
2)脊椎動物におけるIGF-I受容体活性化リガンドに起因する細胞増殖性疾患における細胞増殖を抑制する。
3)IGF-I受容体活性化リガンドによる脊椎動物由来細胞の増殖を阻害する用量において、分化筋細胞でのグルコース取込みに影響しない。
4)脊椎動物におけるIGF-I受容体活性化リガンドに起因する細胞増殖性疾患における細胞増殖を抑制する用量において、当該脊椎動物の血糖値を変動させない。
[23]担癌モデル動物において、血糖値に影響を与えることなく、がん細胞増殖抑制作用を誘導しうる、項[1]~[22]の何れか一項に記載のヒト化抗体若しくはその断片、又はそれらの誘導体。
[24]担癌モデル動物において、がん細胞増殖抑制作用を誘導しうる有効用量に対して10倍以上の血中曝露量においても、当該モデル動物の血糖値に影響を与えない、項[23]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
[25]項[1]~[24]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体をコードするポリヌクレオチド配列を含む核酸分子。
[26]項[25]に記載の核酸分子を少なくとも一つ含むクローニングベクター又は発現ベクター。
[27]項[26]に記載のベクターが宿主細胞に導入された組換え体細胞。
[28]項[1]~[24]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体を製造する方法であって、項[27]に記載の組換え体細胞を培養し、前記組換え体細胞から産生される当該抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体を精製する工程を含む方法。
[29]項[1]~[24]の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体、項[25]に記載の核酸分子、項[26]に記載のベクター、或いは項[27]に記載の組換え体細胞を有効成分として含む、医薬組成物。
[30]筋萎縮性疾患又は低身長症の治療に用いられる、項[29]に記載の医薬組成物。
[31]筋萎縮性疾患が、廃用性筋萎縮、サルコペニア、又はカヘキシアである、項[30]に記載の医薬組成物。
[32]低身長症が、ラロン型低身長症又は成長ホルモン抵抗性低身長症である、項[28]に記載の医薬組成物。
[33]IGF-1受容体に関連した疾患の治療に用いられる、項[29]に記載の医薬組成物。
[34]IGF-I受容体に関連した疾患が、肝臓がん、神経芽細胞腫、横紋筋肉腫、骨肉腫、小児がん、先端巨大症、卵巣がん、膵臓がん、良性前立腺肥大症、乳がん、前立腺がん、骨がん、肺がん、結腸直腸がん、頚部がん、滑膜肉腫、膀胱がん、胃がん、ウィルムス腫瘍、転移性カルチノイド及び血管作動性腸管ペプチド分泌腫瘍に関連する下痢、ビポーマ、ウェルナー-モリソン症候群、ベックウィズ-ヴィーデマン症候群、腎臓がん、腎細胞がん、移行上皮がん、ユーイング肉腫、白血病、急性リンパ芽球性白血病、脳腫瘍、膠芽腫、非膠芽腫性脳腫瘍、髄膜腫、下垂体腺腫、前庭神経鞘腫、未分化神経外胚葉性腫瘍、髄芽腫、星状細胞腫、乏突起膠腫、脳室上衣腫、脈絡叢乳頭腫、巨人症、乾癬、アテローム性動脈硬化症、血管の平滑筋再狭窄、不適切な微小血管増殖、糖尿病性網膜症、グレーヴズ病、多発性硬化症、全身性エリテマトーデス、重症筋無力症、自己免疫性甲状腺疾患、橋本甲状腺炎、甲状腺眼症、甲状腺機能亢進症ならびにベーチェット病からなる群より選択される疾患である、項[33]に記載の医薬組成物。
本開示において「IGF」とは、インスリン様成長因子(Insulin-like Growth Factor)のことをいい、IGF-1とIGF-2が存在する。IGF-1及びIGF-2は、後述のIGF-1受容体(インスリン様成長因子-I受容体:Insulin-like Growth Factor-I Receptor)に結合して、細胞内に細胞分裂や代謝のシグナルを入れるアゴニスト活性を有する生体内のリガンドである。IGF-1及びIGF-2は、IGF-1受容体と構造的に類似性のあるインスリン受容体(INSR)にも弱く交差的に結合することが知られている。本明細書では、生理的機能等がよりよく知られているIGF-1を主に扱うが、IGF-1受容体とリガンドとの結合を介する作用や疾患等の検討を行う場合には、IGF-1とIGF-2の両者の作用を含めて記載することがある。
本開示において「IGF-1受容体」又は「IGF-1R」とは、インスリン様成長因子-I受容体(Insulin-like Growth Factor-I Receptor)のことをいう。本明細書において「IGF-1受容体」は、特に断りがない限り、IGF-1受容体タンパク質を意味する。IGF-1受容体はα鎖とβ鎖からなるサブユニットが2つ会合した構造のタンパク質である。配列番号71に示したヒトIGF-1受容体のアミノ酸配列においては、そのアミノ酸配列のうち、31位から735位のアミノ酸配列からなる部分がα鎖に相当し、β鎖は740位以降の配列に相当する。IGF-1受容体のα鎖はIGF-1の結合部分を有し、β鎖は膜貫通型の構造であり、細胞内へのシグナルを伝える働きをする。IGF-1受容体のα鎖は、L1、CR、L2、FnIII-1及びFnIII-2a/ID/FnIII-2bのドメインに分かれる。配列番号71に示したヒトIGF-1受容体のアミノ酸配列においては、31位から179位の部分がL1ドメイン、180位から328位の部分がCRドメイン、329位から491位の部分がL2ドメイン、492位から607位の部分がFnIII-1ドメイン及び608位から735位までがFnIII-2a/ID/FnIII-2bドメインに相当する。ヒトのIGF-1受容体のアミノ酸配列は、EMBL-EBIのUniProtKB-アクセッション番号P08069等から参照することが可能であるが、配列表の配列番号71にも示す。
マウス親抗体IGF11-16は、特許文献1に開示されている。IGF11-16のCDR-H1のアミノ酸配列は配列番号85、CDR-H2のアミノ酸配列は配列番号86、CDR-H3のアミノ酸配列は配列番号87、CDR-L1のアミノ酸配列は配列番号88、CDR-L2のアミノ酸配列は配列番号89、CDR-L3のアミノ酸配列は配列番号90、重鎖可変領域のアミノ酸配列は配列番号39(対応する核酸塩基配列の一例を配列番号40)、軽鎖可変領域のアミノ酸配列は配列番号41(対応する核酸塩基配列の一例を配列番号42)に示す。IGF11-16の軽鎖の全長アミノ酸配列を配列番号91(対応する核酸塩基配列の一例を配列番号92)に、重鎖の全長アミノ酸配列を配列番号93(対応する核酸塩基配列の一例を配列番号94)に示す。IGF11-16の表現を含む抗体は、全てこのマウス親抗体IGF11-16を意味する。
本発明の一側面によれば、新規な抗IGF-1受容体ヒト化抗体が提供される(これを以下適宜「本発明の抗体」と称する。)。
本開示において「抗体」とは、ジスルフィド結合により相互結合された少なくとも2つの重(H)鎖及び2つの軽(L)鎖を含む糖タンパク質である。それぞれの重鎖は、重鎖可変領域(VHと略される)及び重鎖定常領域を含み、重鎖定常領域は、3つのドメイン、CH1、CH2及びCH3を含む。それぞれの軽鎖は、軽鎖可変領域(VLと略される)及び軽鎖定常領域を含む。軽鎖定常領域は、1つのドメイン、CLを含む。軽鎖の定常領域にはλ鎖及びκ鎖と呼ばれる2種類が存在する。重鎖の定常領域にはγ鎖、μ鎖、α鎖、δ鎖及びε鎖が存在し、その重鎖の違いによって、それぞれIgG、IgM、IgA、IgD及びIgEという抗体のアイソタイプが存在する。VH及びVLは、更にフレームワーク領域(FR)と称される、より保存されている4つの領域(FR-1(FR1)、FR-2(FR2)、FR-3(FR3)、FR-4(FR4))と、相補性決定領域(CDR)と称される超可変性の3つの領域(CDR-1(CDR1)、CDR-2(CDR2)、CDR-3(CDR3))に細分される。VHは、アミノ末端からカルボキシ末端へ、FR-1(FR-H1)、CDR-1(CDR-H1)、FR-2(FR-H2)、CDR-2(CDR-H2)、FR-3(FR-H3)、CDR-3(CDR-H3)、FR-4(FR-H4)の順番で配列された3つのCDR及び4つのFRを含む。VLは、アミノ末端からカルボキシ末端へ、FR-1(FR-L1)、CDR-1(CDR-L1)、FR-2(FR-L2)、CDR-2(CDR-L2)、FR-3(FR-L3)、CDR-3(CDR-L3)、FR-4(FR-L4)の順番で配列された3つのCDR及び4つのFRを含む。重鎖及び軽鎖の可変領域は、抗原と相互作用する結合ドメインを含む。
(2)脂肪族ヒドロキシル側鎖を有するアミノ酸残基:セリン(Ser又はS)及びトレオニン(Thr又はT)残基。
(3)アミド含有側鎖を有するアミノ酸残基:アスパラギン(Asn又はN)及びグルタミン(Gln又はQ)残基。
(4)芳香族側鎖を有するアミノ酸残基:フェニルアラニン(Phe又はF)、チロシン(Tyr又はY)、トリプトファン(Trp又はW)及びヒスチジン(His又はH)残基。
(5)塩基性側鎖を有するアミノ酸残基:リシン(LysまたK)、アルギニン(Arg又はR)及びヒスチジン(His又はH)残基。
(6)酸性側鎖を有するアミノ酸残基:アスパラギン酸(Asp又はD)及びグルタミン酸(Glu又はE)残基。
(7)硫黄含有側鎖を有するアミノ酸基:システイン(Cys又はC)、及びメチオニン(Met又はM)残基。
抗医薬品抗体(Anti-Drug Antibody:ADA)は、治療用抗体の効果及び薬物動態に影響を及ぼし、時に重篤な副作用をもたらすことがあるため、臨床における治療用抗体の有用性及び薬効はADAの産生によって制限され得る。多くの要因が治療用抗体の免疫原性に影響を及ぼすが、治療用タンパク質中に存在するエフェクターT細胞エピトープの重要性が多数報告されている。T細胞エピトープを予測するためのin silicoツールとしては、Epibase(Lonza)、iTope/TCED(Antitope)、及びEpiMatrix(EpiVax)等が開発されている。これらのin silicoツールを用いることで、各アミノ酸配列中のT細胞エピトープの存在を予測することができ(非特許文献21)、潜在的免疫原性の評価が可能になる。本発明の抗IGF-1受容体ヒト化抗体に関しては、Epibase(Lonza)を用いて、潜在的免疫原性を評価した。
タンパク質を構成するアミノ酸配列のうち、脱アミド化が起こりやすいアミノ酸配列として、NG、NT、NS、及びNNが挙げられる。これらの配列を有するとアスパラギンの脱アミド化が起こり、アスパラギン酸へと変化する。このことにより、抗体の活性が低下してしまう恐れがあると共に、品質が均一でなくなる。このことから製造工程や保管において品質を保つために、脱アミド化リスクのあるアミノ酸を別のアミノ酸へ置換することによって活性低下を防ぎ均一性を保持することが可能である。本発明の抗体においては、マウス親抗体IGF11-16の重鎖CDR-2(CDR-H2)領域にNS配列(重鎖55位及び56位)が存在したため、重鎖55位のアスパラギン(N)が脱アミド化してアスパラギン酸(D)へ変換されるリスクを考慮して、当該アスパラギン(N)をセリン(S)に置換した。
抗体の活性が長期に安定に保持されることを保証するために、温度を上昇させたり、pHを変化させたりすることで物性安定性の解析を行う。本発明の抗IGF-1受容体ヒト化抗体においては、本抗体のPBS溶液を使用して、温度を37℃に設定し1ヶ月間インキュベーションした試料を使用して、純度が95%以上であること及び凝集物が生じないことを確認することで、物性安定性を確認した。
一態様によれば、本発明の抗体は、IGF-1受容体のCRドメインをエピトープとする。好ましくは、本発明の抗体は、ヒトIGF-1受容体のアミノ酸配列(配列番号71)のうち、アミノ酸番号308から319に相当するアミノ酸配列(ProSerGlyPheIleArgAsnGlySerGlnSerMet)を有するペプチドを含むエピトープ又はその近傍に結合する。本発明の抗体は、IGF-1受容体のCRドメインに結合することにより、IGF-1受容体が二量体を形成したホモ型の受容体、或いはIGF-1受容体とINSRが二量体を形成したヘテロ型の受容体を活性化させると考えられる。
本発明のアゴニスト抗体は、ヒトIgGクラス又はその変異体であることが好ましく、ヒトIgG4サブクラス若しくはその変異体、又は、ヒトIgG1サブクラス若しくはその変異体であることが好ましい。1つの例では、安定化IgG4定常領域は、Kabatの系により、ヒンジ領域の位置241においてプロリンを含む(非特許文献22)。この位置は、EU付番方式(非特許文献13)により、ヒンジ領域の位置228に対応する。ヒトIgG4では、この残基は一般的にセリンであり、セリンのプロリンへの置換で安定化を誘導することができる。1つの例では、IgG1の定常領域にN297A変異を組み入れてFc受容体への結合及び/又は補体を固定する能力をできるだけ抑えることができる。また、別の態様では、定常領域にアミノ酸置換を導入することでFcRnへの結合を調節し、血中半減期を長くすることも出来る。しかし、定常領域のアミノ酸置換はこれらの例示に限定されるものではない。
本発明の抗IGF-1受容体ヒト化抗体は、その極めて高い結合性及び特異性を有する可変領域の性質を利用して、優れた活性と特異性を有する抗IGF-1受容体アンタゴニスト抗体とすることができる。その際の態様としては、IgGの他にFabやFv、scFv、VHHのような形で使用することが考えられるが、これに限定されるものでは無い。
これらの作用は、担癌モデル動物等を用いて確認することができる。
本発明の抗IGF-1受容体抗体の極めて高い結合性と特異性を利用してIGF-1受容体発現細胞や発現組織などへ薬剤や抗体の局所デリバリーが可能である。その際の本発明の抗IGF-1受容体抗体の態様としては、IgGの他にFabやFv、scFv、VHHのような形で使用することが考えられるが、これに限定されるものでは無い。本発明の抗IGF-1受容体抗体と薬剤が連結された抗体薬物複合体の利用によって、薬剤が局所へ送達されることで、より低用量で特異的に薬効を発揮させることが出来、副作用の低減にもつながる。
本発明の抗IGF-1受容体抗体と、IGF-1受容体に対して競合結合する抗体も、本発明の範囲に含まれる。本発明において「競合結合」とは、複数種のモノクローナル抗体が抗原と共存する際に、一方の抗体の抗原への結合が、他方の抗体の抗原への結合により阻害される現象を意味する。一般的には、一定量(濃度)のモノクローナル抗体に対して、別のモノクローナル抗体の量(濃度)を変えて加えていった場合に、前者の一定量のモノクローナル抗体の抗原への結合量が低下する添加量(濃度)を測定することによって測定可能である。その阻害の程度は、IC50又はKiという値で表すことができる。
本発明の抗体は、他の脊椎動物のIGF-1受容体に対して交差反応を有する。交差反応とは、その抗体が抗原抗体反応をするIGF-1受容体の動物種(例えばヒト)とは異なる他の動物種のIGF-1受容体にして抗体が結合性を示すことをいう。本発明の抗IGF-1受容体ヒト化抗体はヒト以外にモルモット、サル、ウサギなどのIGF-1受容体と交差反応性を示す。一方、マウス及びラットのIGF-1受容体には交差反応性を示さない。
本発明の抗IGF-1受容体ヒト化抗体は、マウス親抗体IGF11-16(特許文献1)と同等以上のレベルの極めて強い結合親和性を有している。その結合親和性の評価は、たとえば、組換えIGF-1受容体の細胞外領域を抗原として使用し、SPR(表面プラズモン共鳴)解析によって行うことが出来る。実施例においては、BIACOREを使用して反応温度を40℃に上げて、抗原固定量を低く抑えることで1価の結合親和性を解析しているが、この方法に限定されるものではなく、強い結合親和性を定量的に評価し得る解析方法であれば良い。
本発明の抗IGF-1受容体ヒト化抗体は、IGF-1受容体シグナル活性化を1次評価系として使用することで、マウス親抗体IGF11-16(特許文献1)と同等以上のレベルのヒト化抗体を選択することにより得られたものである。
本発明のヒト化抗体の2次評価系としてヒト筋芽細胞増殖評価を行い、マウス親抗体IGF11-16(特許文献1)と同等の濃度域で同等以上のアゴニスト活性を有するヒト化抗体を絞り込んだ。そのようにして選択された本発明のヒト化抗体はインビボ(in vivo)において血糖低下作用を示さず、筋量増加作用を有することが確認された。すなわち、一態様における本発明の抗IGF-1受容体ヒト化抗体は、脊椎動物由来細胞の増殖誘導活性を有する。
一態様によれば、本発明の抗体は、脊椎動物での血糖値に影響を及ぼさないという特徴を有する。IGF-1は、IGF-1受容体へのアゴニスト作用の一部として、血糖値の低下作用を起こすことが知られている。しかし、抗IGF-1受容体アゴニスト抗体として機能する本発明のアゴニスト抗体は、動物に非経口的に投与した場合に筋肉量の増加を誘導する有効用量の更に10倍以上の血中曝露量でも、血糖値を変動させないという特徴を示す。
本発明の抗体は、IGF-1受容体に対するマウスモノクローナル抗体IGF11-16(特許文献1)をヒト化することにより取得できる。ヒト以外の動物種から得られたモノクローナル抗体を使用してそのCDR領域をCDRグラフティングによってヒトフレームワークに置き換えることをヒト化という(非特許文献12)。さらに3次元構造解析により、立体構造を維持しながら、ヒトへの免疫原性(T細胞抗原性)を低下させるためのアミノ酸置換や、脱アミド化や酸化などの翻訳後修飾リスクを回避するためのアミノ酸置換を導入することで、活性を維持しつつ製造性や臨床での安全性を確保したヒト化抗体を作製する。
本発明の抗体は、IGF-1に関連した状態又はIGF-1受容体への作用に起因する疾患の治療薬又は予防薬又は診断薬として利用可能である。以降、治療薬・予防薬又は診断薬を総称して「薬」又は「薬剤」と記載する。
・ヒトフレームワークの選定
Kohlerら(Nature, (1975), Vol.256, pp.495-497)のハイブリドーマ法により作製し得られたIGF-1受容体に対するマウスモノクローナル抗体IGF11-16(特許文献1)の重鎖可変領域(VH)及び軽鎖可変領域(VL)中の相補性決定領域(CDR)アミノ酸を、鋳型ヒト抗体に移植した。移植先となる鋳型ヒト抗体としては、マウス抗体IGF11-16(マウス親抗体)のVH及びVLのアミノ酸配列(それぞれ配列番号39及び配列番号41)に対して、それらと相同性の高いアミノ酸配列を持つヒト抗体の生殖細胞系列(germline)の中から、重鎖配列としてVH-1-46(配列番号95)及びVH-1-e(配列番号96)、重鎖J-セグメントとしてJH4(配列番号97)、軽鎖配列としてVK1-L5(配列番号98)及びVK1-A20(配列番号99)、軽鎖J-セグメントとしてJK2(配列番号100)を選択し、これらを以下の表1に示すように組み合わせた2通りのヒト化抗体フレームワークを用いた。
上記の鋳型ヒト抗体VH及びVLのFRに、マウス抗体IGF11-16のVH及びVLから必要なアミノ酸配列を移植してヒト化抗体を作製した。
なお、本実施例の記載及び図面中において、デザインされたヒト化抗体重鎖可変領域と重鎖定常領域とを連結して構成されるヒト化重鎖、デザインされたヒト化抗体軽鎖可変領域と軽鎖定常領域とを連結して構成されるヒト化軽鎖、更にはそれらのヒト化重鎖とヒト化軽鎖とを組み合わせて構成される完全ヒト化抗体を、使用した重鎖可変領域及び/又は軽鎖可変領域の名称により略称する場合がある。例えば、図1A中の“VL22/VH13_PS”とは、VL22を軽鎖可変領域とし、これにヒトκ鎖定常領域を連結した軽鎖と、VH13_PSを重鎖可変領域とし、これにIgG4S228P重鎖定常領域を連結した重鎖とを組み合わせて構成されるヒト化抗体を指す。 また、配列番号15、17、19、21、23、25及び27のアミノ酸配列に対応する核酸塩基配列の一例を、それぞれ配列番号16、18、20、22、24、26及び28に示す。
デザインしたヒト化抗体の重鎖可変領域と、ヒトIgG4サブクラスを安定化した変異体であるヒトIgG4S228P変異体の重鎖定常領域をコードするDNAをそれぞれ合成し、pcDNA3.4系発現ベクターに組み込み連結し、ヒト化抗体重鎖を発現するプラスミドとした。
以降のヒト化抗体の調製に関しては、上述の方法に準じて行った。
デザインされたヒト化抗体のIGF-1受容体に対する活性化作用を検出するために、PathHunter(登録商標)IGF1R Functional Assay(DiscoverX)を用いて、以下の手順によりIGF-1受容体シグナルの活性化を測定した。
CDR領域において、活性を保持するために必要なアミノ酸を同定する目的で、マウス親抗体IGF11-16においてそれぞれのアミノ酸をアラニン置換し、その置換体のシグナル活性化能をEC50値とEmax値で比較し、結合活性を抗原ELISAで評価した。マウス親抗体IGF11-16と比較してEC50値:2倍以内、Emax値:±20%以内を同等の活性と定義した。
一方、アラニン置換したCDR領域におけるアミノ酸残基54部位のうち、44部位はアラニン置換後も80%以上の結合活性を示した。
実施例3の結果から重鎖の25位のプロリンが活性維持に重要なことが判明したため、重鎖の25位をPとして、ヒト化重鎖可変領域FW1_VH1及びFW2_VH1を基本骨格としてデザインを行った。FW1_VH1のFR1を基本としてアミノ酸置換体を検討したため、FW2-VH1のFR1部分はFW1_FR1と同一にするため、S16Aのアミノ酸置換を行った。また、免疫原性低減のためのアミノ酸置換導入は、Epibase(登録商標)(Lonza社)の免疫原性スコア解析結果に基づいて実施した。デザインされた重鎖可変領域リストを以下の表9に示す。
ヒト化軽鎖可変領域に関しては、FW1_VL1及びFW2_VL2を基本骨格としてデザインを行った。免疫原性スコア低下のためのアミノ酸置換導入は、Epibase(登録商標)(Lonza社)の解析結果に基づいて実施した。デザインされた軽鎖可変領域リストを表に示す。
ヒト化抗体を製造する際に脱アミド化が起こると品質管理が困難となる。そのため、事前に脱アミド化リスクのあるアミノ酸は、活性に影響のない別のアミノ酸へ置換することが必要である。一般的に脱アミド化リスクのある配列としてNG、NT、NS、及びNNが挙げられる。本ヒト化抗体の重鎖のCDR-H2領域においてNS配列が存在する。故に、55位のアスパラギン(N)が脱アミド化してアスパラギン酸(D)へ変換されるリスクを考慮してアミノ酸置換を行った。置換した重鎖のリストを表11に示す。また、配列番号45、51、及び57のアミノ酸配列に対応する核酸塩基配列の一例を、それぞれ配列番号46、52、及び58に示す。
ヒト化抗体をIGF-1受容体の活性化作用に基づいて評価し、マウス親抗体IGF11-16と同等の活性を有するヒト化抗体を選択した。
ヒト化抗体をヒト筋芽細胞増殖活性に基づいて評価し、マウス親抗体IGF11-16と同等の活性を有するヒト化抗体を選択した。
ヒト化抗体の免疫原性を解析するために、LonzaのEpibase(登録商標)in Silicoを使用し、免疫原性スコアを算出した。LonzaのEpibase(登録商標)in Silicoプラットフォームは、既に実験的に決定された10-merのペプチドとHLA class II受容体の結合親和性とともにHLA class II受容体の構造特性を使用して、抗体に含まれるアミノ酸配列中に存在するT細胞の活性化に必要な条件である潜在的なペプチド/HLA結合を予測し、免疫原性スコアとして算出する免疫原性予測方法である。85種類のHLAクラスIIアロタイプ(43種のDRB1、8種のDRB3/4/5、22種のDQ、12種のDP)における評価をすることで、全人口の99%以上をカバーすることができる。免疫原性スコアは、アロタイプの結合親和性に加えて出現頻度などを加味してスコア化された。
ヒト(配列番号71)、カニクイザル(配列番号73)、ウサギ(配列番号75)、モルモット(配列番号77)、ラット(配列番号79)及びマウス(配列番号81)のIGF-1受容体に対する抗IGF-1受容体アゴニスト抗体の結合活性を検討するために、各種IGF-1受容体を発現させた細胞を用いてCell-based ELISAを実施した。
薬剤のIGF-1受容体に対する結合特性(結合速度及び解離速度)を検討するために、表面プラズモン共鳴(SPR)法により測定した。
抗IGF-1受容体アゴニスト抗体のインビボでの血糖低下作用の有無を確認するために、モルモットにhIGF13_PS及びhIGF25_PSを単回投与して、継時的に血糖値を測定して、血糖低下作用の有無を検討した。血糖低下作用とは、血糖値を50mg/dL以下に低下させる、又は低血糖症状を起こす作用とする。
モルモットを12時間絶食させ、ヒト化抗体hIGF13_PS及びhIGF25_PS又はIGF11-16(マウス親抗体)を、1及び10mg/kgで単回静脈内投与した。モルモットは、投与24時間後まで絶食させ、24時間後に再給餌した。覚醒状態のモルモットを、投与前(0時間)、投与2、4、8、24、48、72、96、120、及び144時間後に採血して、血漿中のヒト化抗体濃度をELISAにより測定した。
正常モルモットにhIGF13_PSを静脈内へ単回投与して、2週間後の筋質量を測定し、IGF-1の持続投与及びマウス親抗体IGF11-16の静脈内投与した時の筋量増加作用と比較した。
hIGF13_PSの成長板軟骨増殖作用評価としてモルモット下垂体摘出(HPX)モデルを用いて脛骨近位部の骨端線厚(Epiphyseal line thicknes)を評価した。モルモット下垂体摘出(HPX)モデルは、下垂体摘出によって成長ホルモンの産生が抑制されるため、低IGF-1状態となる。
抗IGF-1受容体アゴニスト抗体のカニクイザルにおける血糖低下作用の有無を確認するために、カニクイザルにhIGF13_PSを単回投与して、継時的に血糖値を測定して、IGF-1(1mg/kg)の単回投与時の血糖低下作用と比較した。血糖低下作用とは、溶媒投与群と比較して50%未満に低下させる、又は低血糖症状を起こす作用とする。
ヒト化抗体hIGF13_PSを、1及び10mg/kgでカニクイザルへ単回静脈内又は皮下投与した。投与前(0時間)、投与2、4、8、24、48、72、及び144時間後に採血して、血漿中のヒト化抗体濃度をELISAにより測定した。
カニクイザル2個体に対して、hIGF13_PSを1mg/kgで静脈内投与を実施した。投与前と投与後3~4週間後においてDXA(Dual Energy X-ray Absorptiometry)法によって筋肉量を測定した。
マウス親抗体IGF11-16がHepG2細胞増殖に対して及ぼす濃度依存的な作用を細胞生存アッセイにより評価した。
IGF-1によるヒト乳がん細胞株(MCF7)増殖活性に対するIGF11-16の作用を評価するため、50nM IGF11-16を共存させた条件下でhIGF-1(メカセルミン)の濃度依存的な増殖活性を、添加2日後の細胞内のATP量によって測定した。
Claims (34)
- マウス親抗体IGF11-16に由来する重鎖及び軽鎖の各相補性決定領域(CDR)と、ヒト抗体に由来する重鎖及び軽鎖の各フレームワーク領域(FR)とを含むと共に、少なくとも1つのCDRが、マウス親抗体IGF11-16の対応するCDRに対して、少なくとも1箇所のアミノ酸残基の置換を含む、抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 重鎖可変領域のフレームワーク領域1(FR-H1)の25位のアミノ酸残基がプロリンである、請求項1に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 重鎖可変領域のCDR-1(CDR-H1)配列として、配列番号1のアミノ酸配列、又は、配列番号1の何れか1箇所のアミノ酸残基が置換されたアミノ酸配列、
重鎖可変領域のCDR-2(CDR-H2)配列として、配列番号3若しくは配列番号5のアミノ酸配列、又は、配列番号3若しくは配列番号5の何れか1箇所、2箇所、若しくは3箇所のアミノ酸残基が置換されたアミノ酸配列、
重鎖可変領域のCDR-3(CDR-H3)配列として、配列番号7のアミノ酸配列、又は、配列番号7の何れか1箇所若しくは2箇所のアミノ酸残基が置換されたアミノ酸配列、
軽鎖可変領域のCDR-1(CDR-L1)配列として、配列番号9のアミノ酸配列、又は、配列番号9の何れか1箇所若しくは2箇所のアミノ酸残基が置換されたアミノ酸配列、
軽鎖可変領域のCDR-2(CDR-L2)配列として、配列番号11のアミノ酸配列、又は、配列番号11の何れか1箇所のアミノ酸残基が置換されたアミノ酸配列、
軽鎖可変領域のCDR-3(CDR-L3)配列として、配列番号13のアミノ酸配列、又は、配列番号13の何れか1箇所若しくは2箇所のアミノ酸残基が置換されたアミノ酸配列
を含む、請求項1又は2に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。 - 重鎖可変領域のCDR-1(CDR-H1)配列として、配列番号1と80%以上の相同性を有するアミノ酸配列、
重鎖可変領域のCDR-2(CDR-H2)配列として、配列番号3又は配列番号5と82%以上の相同性を有するアミノ酸配列、
重鎖可変領域のCDR-3(CDR-H3)配列として、配列番号7と75%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-1(CDR-L1)配列として、配列番号9と81%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-2(CDR-L2)配列として、配列番号11と85%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-3(CDR-L3)配列として、配列番号13と77%以上の相同性を有するアミノ酸配列
を含む、請求項1又は2に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。 - 重鎖可変領域のCDR-1(CDR-H1)配列として、配列番号1の3位のTrpが維持され、又は、類似のアミノ酸残基に置換されたアミノ酸配列であって、当該3位のアミノ酸残基以外の何れか1箇所のアミノ酸残基が置換され、又は、配列番号1と80%以上の相同性を有するアミノ酸配列、
重鎖可変領域のCDR-2(CDR-H2)配列として、
配列番号3の1位のGlu及び3位のAsnが各々維持され、又は、類似のアミノ酸残基に置換されると共に、6位のAsnが維持され、又は、Ser若しくはGlnに置換されたアミノ酸配列であって、当該1位、3位、及び6位のアミノ酸残基以外の何れか1箇所、2箇所、若しくは3箇所のアミノ酸残基が置換され、又は、配列番号3と82%以上の相同性を有するアミノ酸配列、或いは、
配列番号5の1位のGlu及び3位のAsnが各々維持され、又は、類似のアミノ酸残基に置換されると共に、6位のSerが維持され、又は、Asn若しくはGlnに置換されたアミノ酸配列であって、当該1位、3位、及び6位のアミノ酸残基以外の何れか1箇所、2箇所、若しくは3箇所のアミノ酸残基が置換され、又は、配列番号5と82%以上の相同性を有するアミノ酸配列、
重鎖可変領域のCDR-3(CDR-H3)配列として、配列番号7の4位のArgが維持され、又は、類似のアミノ酸残基に置換されたアミノ酸配列であって、当該4位のアミノ酸残基以外の何れか1箇所若しくは2箇所のアミノ酸残基が置換され、又は、配列番号7と75%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-1(CDR-L1)配列として、配列番号9の9位のTrpが維持され、又は、類似のアミノ酸残基に置換されたアミノ酸配列であって、当該9位のアミノ酸残基以外の何れか1箇所若しくは2箇所のアミノ酸残基が置換され、又は、配列番号9と81%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-2(CDR-L2)配列として、配列番号11の何れか1箇所のアミノ酸残基が置換され、又は、配列番号11と85%以上の相同性を有するアミノ酸配列、
軽鎖可変領域のCDR-3(CDR-L3)配列として、配列番号13の何れか1箇所若しくは2箇所のアミノ酸残基が置換され、又は、配列番号13と77%以上の相同性を有するアミノ酸配列
を含む、請求項1又は2に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。 - 配列番号71のアミノ酸配列を有するヒトIGF-1受容体の細胞外ドメインに特異的に結合する、請求項1~5の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 重鎖可変領域として、配列番号43、47、49、53、55、若しくは59のアミノ酸配列、配列番号43、47、49、53、55、若しくは59のアミノ酸配列において1若しくは数箇所のアミノ酸残基が置換、欠失、若しくは付加されたアミノ酸配列、又は、配列番号43、47、49、53、55、若しくは59と90%以上の相同性を有するアミノ酸配列、及び、
軽鎖可変領域として、配列番号65、67、若しくは69のアミノ酸配列、配列番号65、67、若しくは69のアミノ酸配列において1若しくは数箇所のアミノ酸残基が置換、欠失、若しくは付加されたアミノ酸配列、又は、配列番号65、67、若しくは69と90%以上の相同性を有するアミノ酸配列
を含む、請求項1~6の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。 - 重鎖及び/又は軽鎖の定常領域として、ヒト免疫グロブリンの何れかのクラスの重鎖及び/又は軽鎖の定常領域を含む、請求項1~7の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 重鎖定常領域が、ヒトIgG4クラスの重鎖定常領域又はその1~10箇所のアミノ酸が置換された定常領域である、請求項1~8の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 重鎖定常領域が、ヒトIgG1クラスの重鎖定常領域又はその1~10箇所のアミノ酸が置換された定常領域である、請求項1~8の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- IGF-1受容体に対して平衡解離定数(KD)1×10-7M以下の親和性で結合する、請求項1~10の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- IGF-1受容体シグナル活性化能を有する、請求項1~11の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 筋芽細胞増殖試験において、増殖活性を有する、請求項1~12の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- BIACOREによる組換え可溶性IGF-1受容体への結合性試験において、マウス親抗体IGF11-16と同等以上の結合親和性を有する、請求項1~13の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 正常哺乳動物において、低血糖症状を誘導せず、筋量増加作用を誘導しうる、請求項1~14の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 下垂体摘出モデル動物において、低血糖症状を誘導せず、成長板軟骨伸長作用を誘導しうる、請求項1~15の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 脊椎動物の筋肉量及び/又は体長の増加を誘導する用量において当該脊椎動物に投与された場合に、当該脊椎動物の血糖値を低下させない、請求項1~16の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 脊椎動物の筋肉量及び/又は体長の増加を誘導する有効用量に対して10倍以上の血中曝露量においても、当該脊椎動物の血糖値を低下させない、請求項1~16の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- IGF-1受容体シグナル活性化抑制能を有する、請求項1~18の何れか一項に記載のヒト化抗体若しくはその断片、又はそれらの誘導体。
- 筋芽細胞増殖試験において、IGF-1受容体を活性化しうるリガンドであるIGF-1、IGF-2、及びインスリンの少なくとも一つの増殖活性を抑制する、請求項1~18の何れか一項に記載のヒト化抗体若しくはその断片、又はそれらの誘導体。
- がん細胞増殖試験において、細胞増殖を抑制する活性を有する、請求項1~20の何れか一項に記載のヒト化抗体若しくはその断片、又はそれらの誘導体。
- 抗IGF-I受容体抗体もしくはその断片、又はそれらの誘導体が、1)~4)の少なくとも一つの特徴を有する、請求項1~21のいずれか一項に記載の抗IGF-I受容体抗体もしくはその断片、又はそれらの誘導体。
1)IGF-I受容体活性化リガンドによる脊椎動物由来細胞の増殖を阻害する。
2)脊椎動物におけるIGF-I受容体活性化リガンドに起因する細胞増殖性疾患における細胞増殖を抑制する。
3)IGF-I受容体活性化リガンドによる脊椎動物由来細胞の増殖を阻害する用量において、分化筋細胞でのグルコース取込みに影響しない。
4)脊椎動物におけるIGF-I受容体活性化リガンドに起因する細胞増殖性疾患における細胞増殖を抑制する用量において、当該脊椎動物の血糖値を変動させない。 - 担癌モデル動物において、血糖値に影響を与えることなく、がん細胞増殖抑制作用を誘導しうる、請求項1~22の何れか一項に記載のヒト化抗体若しくはその断片、又はそれらの誘導体。
- 担癌モデル動物において、がん細胞増殖抑制作用を誘導しうる有効用量に対して10倍以上の血中曝露量においても、当該モデル動物の血糖値に影響を与えない、請求項23に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体。
- 請求項1~24の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体をコードするポリヌクレオチド配列を含む核酸分子。
- 請求項25に記載の核酸分子を少なくとも一つ含むクローニングベクター又は発現ベクター。
- 請求項26に記載のベクターが宿主細胞に導入された組換え体細胞。
- 請求項1~24の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体を製造する方法であって、請求項27に記載の組換え体細胞を培養し、前記組換え体細胞から産生される当該抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体を精製する工程を含む方法。
- 請求項1~24の何れか一項に記載の抗IGF-1受容体ヒト化抗体若しくはその断片、又はそれらの誘導体、請求項25に記載の核酸分子、請求項26に記載のベクター、或いは請求項27に記載の組換え体細胞を有効成分として含む、医薬組成物。
- 筋萎縮性疾患又は低身長症の治療に用いられる、請求項29に記載の医薬組成物。
- 筋萎縮性疾患が、廃用性筋萎縮、サルコペニア、又はカヘキシアである、請求項30に記載の医薬組成物。
- 低身長症が、ラロン型低身長症又は成長ホルモン抵抗性低身長症である、請求項30に記載の医薬組成物。
- IGF-1受容体に関連した疾患の治療に用いられる、請求項29に記載の医薬組成物。
- IGF-I受容体に関連した疾患が、肝臓がん、神経芽細胞腫、横紋筋肉腫、骨肉腫、小児がん、先端巨大症、卵巣がん、膵臓がん、良性前立腺肥大症、乳がん、前立腺がん、骨がん、肺がん、結腸直腸がん、頚部がん、滑膜肉腫、膀胱がん、胃がん、ウィルムス腫瘍、転移性カルチノイド及び血管作動性腸管ペプチド分泌腫瘍に関連する下痢、ビポーマ、ウェルナー-モリソン症候群、ベックウィズ-ヴィーデマン症候群、腎臓がん、腎細胞がん、移行上皮がん、ユーイング肉腫、白血病、急性リンパ芽球性白血病、脳腫瘍、膠芽腫、非膠芽腫性脳腫瘍、髄膜腫、下垂体腺腫、前庭神経鞘腫、未分化神経外胚葉性腫瘍、髄芽腫、星状細胞腫、乏突起膠腫、脳室上衣腫、脈絡叢乳頭腫、巨人症、乾癬、アテローム性動脈硬化症、血管の平滑筋再狭窄、不適切な微小血管増殖、糖尿病性網膜症、グレーヴズ病、多発性硬化症、全身性エリテマトーデス、重症筋無力症、自己免疫性甲状腺疾患、橋本甲状腺炎、甲状腺眼症、甲状腺機能亢進症ならびにベーチェット病からなる群より選択される疾患である、請求項33に記載の医薬組成物。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112022022030A BR112022022030A2 (pt) | 2020-06-02 | 2021-06-01 | Anticorpo humanizado do receptor anti-igf-1, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo para produzir um anticorpo humanizado do receptor anti-igf-1, e, composição farmacêutica |
KR1020227042511A KR20230006006A (ko) | 2020-06-02 | 2021-06-01 | 항 igf-1 수용체 인간화 항체 |
MX2022015133A MX2022015133A (es) | 2020-06-02 | 2021-06-01 | Anticuerpo humanizado anti-receptor de igf-1. |
IL296519A IL296519A (en) | 2020-06-02 | 2021-06-01 | Humanized antibody against igf-1 receptor |
EP21817253.4A EP4159860A1 (en) | 2020-06-02 | 2021-06-01 | Anti-igf-1 receptor humanized antibody |
JP2022528850A JPWO2021246413A1 (ja) | 2020-06-02 | 2021-06-01 | |
AU2021282629A AU2021282629A1 (en) | 2020-06-02 | 2021-06-01 | Anti-IGF-1 receptor humanized antibody |
CA3176119A CA3176119A1 (en) | 2020-06-02 | 2021-06-01 | Anti-igf-1 receptor humanized antibody |
CN202180039577.1A CN115605594A (zh) | 2020-06-02 | 2021-06-01 | 抗igf-1受体人源化抗体 |
CONC2022/0017026A CO2022017026A2 (es) | 2020-06-02 | 2022-11-28 | Anticuerpo humanizado anti– receptor de igf–1 |
JP2024028737A JP2024054410A (ja) | 2020-06-02 | 2024-02-28 | 抗igf-1受容体ヒト化抗体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020096344 | 2020-06-02 | ||
JP2020-096344 | 2020-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021246413A1 true WO2021246413A1 (ja) | 2021-12-09 |
Family
ID=78831168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/020890 WO2021246413A1 (ja) | 2020-06-02 | 2021-06-01 | 抗igf-1受容体ヒト化抗体 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP4159860A1 (ja) |
JP (2) | JPWO2021246413A1 (ja) |
KR (1) | KR20230006006A (ja) |
CN (1) | CN115605594A (ja) |
AR (1) | AR122499A1 (ja) |
AU (1) | AU2021282629A1 (ja) |
BR (1) | BR112022022030A2 (ja) |
CA (1) | CA3176119A1 (ja) |
CL (1) | CL2022003399A1 (ja) |
CO (1) | CO2022017026A2 (ja) |
IL (1) | IL296519A (ja) |
MX (1) | MX2022015133A (ja) |
TW (1) | TW202210513A (ja) |
WO (1) | WO2021246413A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114561337B (zh) * | 2022-03-09 | 2023-10-03 | 广州源井生物科技有限公司 | 一种提高HepG2细胞克隆形成率的单克隆增强培养基和方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015516985A (ja) * | 2012-04-27 | 2015-06-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 抗gcc抗体分子、およびgcc標的化療法への感受性を試験するためのその使用 |
WO2018221521A1 (ja) | 2017-05-30 | 2018-12-06 | 帝人ファーマ株式会社 | 抗igf-i受容体抗体 |
WO2019152571A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
WO2019156565A1 (en) * | 2018-02-12 | 2019-08-15 | Fast Forward Pharmaceuticals B.V. | Improved antagonistic anti-human cd40 monoclonal antibodies |
WO2019175186A1 (en) * | 2018-03-12 | 2019-09-19 | UltraHuman Six Limited | Anti c-met antibodies |
JP2020508666A (ja) * | 2017-02-27 | 2020-03-26 | 帝人ファーマ株式会社 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
WO2020116398A1 (ja) * | 2018-12-03 | 2020-06-11 | 帝人ファーマ株式会社 | 抗igf-i受容体ヒト化抗体 |
-
2021
- 2021-06-01 WO PCT/JP2021/020890 patent/WO2021246413A1/ja active Application Filing
- 2021-06-01 MX MX2022015133A patent/MX2022015133A/es unknown
- 2021-06-01 BR BR112022022030A patent/BR112022022030A2/pt unknown
- 2021-06-01 JP JP2022528850A patent/JPWO2021246413A1/ja active Pending
- 2021-06-01 KR KR1020227042511A patent/KR20230006006A/ko unknown
- 2021-06-01 CN CN202180039577.1A patent/CN115605594A/zh active Pending
- 2021-06-01 AR ARP210101492A patent/AR122499A1/es unknown
- 2021-06-01 CA CA3176119A patent/CA3176119A1/en active Pending
- 2021-06-01 AU AU2021282629A patent/AU2021282629A1/en active Pending
- 2021-06-01 EP EP21817253.4A patent/EP4159860A1/en active Pending
- 2021-06-01 IL IL296519A patent/IL296519A/en unknown
- 2021-06-01 TW TW110119805A patent/TW202210513A/zh unknown
-
2022
- 2022-11-28 CO CONC2022/0017026A patent/CO2022017026A2/es unknown
- 2022-12-01 CL CL2022003399A patent/CL2022003399A1/es unknown
-
2024
- 2024-02-28 JP JP2024028737A patent/JP2024054410A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015516985A (ja) * | 2012-04-27 | 2015-06-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 抗gcc抗体分子、およびgcc標的化療法への感受性を試験するためのその使用 |
JP2020508666A (ja) * | 2017-02-27 | 2020-03-26 | 帝人ファーマ株式会社 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
WO2018221521A1 (ja) | 2017-05-30 | 2018-12-06 | 帝人ファーマ株式会社 | 抗igf-i受容体抗体 |
WO2019152571A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
WO2019156565A1 (en) * | 2018-02-12 | 2019-08-15 | Fast Forward Pharmaceuticals B.V. | Improved antagonistic anti-human cd40 monoclonal antibodies |
WO2019175186A1 (en) * | 2018-03-12 | 2019-09-19 | UltraHuman Six Limited | Anti c-met antibodies |
WO2020116398A1 (ja) * | 2018-12-03 | 2020-06-11 | 帝人ファーマ株式会社 | 抗igf-i受容体ヒト化抗体 |
Non-Patent Citations (26)
Title |
---|
"NCBI", Database accession no. NP 000609 |
"Remington: The Science and Practice of Pharmacy, 20th EDITION", 2000, LIPPINCOTT WILLIAMS & WILKINS |
"UniProtKB", Database accession no. P05019 |
ABHINANDAN, K.R. ET AL., MOLECULAR IMMUNOLOGY, vol. 45, 2008, pages 3832 - 3839 |
ABUZZAHAB, M.J. ET AL.: "IGF-1 receptor mutations resulting in intrauterine and postnatal growth retardation", N ENGL J MED, vol. 349, no. 23, 2003, pages 2211 - 22 |
AL-LAZIKANI ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 273, no. 4, 1997, pages 927 - 948 |
ATZORI, F. ET AL.: "A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors", CLIN CANCER RES., vol. 17, no. 19, 2011, pages 6304 - 12 |
BURKS, E. A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, no. 2, 1997, pages 412 - 417 |
DE BONO J. S. ET AL.: "Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastaticcastration- resistant prostate cancer", CLIN CANCER RES., vol. 20, no. 7, 2014, pages 1925 - 34, XP055687495, DOI: 10.1158/1078-0432.CCR-13-1869 |
DUMET, C. ET AL., MABS, vol. 11, no. 8, 2019, pages 1341 - 1350 |
HUMAN SOMATOMEDIN C: "Somazon Formulation for Injection 10mg", May 2015, article "Drug interview form" |
JIAN, Y. ET AL., NUCLEIC ACIDS RESEARCH, vol. 41, 2013, pages W34 - W40 |
KABAT ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 5, 1991, pages 1709 - 1719 |
KATO, H. ET AL.: "Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-1) receptor. Characterization of kinase-deficient IGF-1 receptors and the action of an IGF-1-mimetic antibody (alpha IR-3).", J BIOL CHEM, vol. 268, no. 4, 1993, pages 2655 - 61, XP008114108 |
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497 |
MARKHAM. A: "Teprotumumab: First Approval", DRUGS, vol. 80, no. 5, 2020, pages 509 - 512 |
MUSARO, A. ET AL.: "Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle", NATURE GENETICS, vol. 27, no. 2, 2001, pages 195 - 200, XP001199471, DOI: 10.1038/84839 |
RIECHMAN, L.CLARK, M.WALDMANN, H.WINTER, G.: "Reshaping human antibodies for therapy.", NATURE, vol. 332, 1988, pages 323 - 327 |
RUNNELS, H.A. ET AL.: "Human monoclonal antibodies to the insulin-like growth factor 1 receptor inhibit receptor activation and tumor growth in preclinical studies", ADV THER, vol. 27, no. 7, 2010, pages 458 - 75, XP002751208, DOI: 10.1007/s12325-010-0026-5 |
SAUNDERS, K. O., FRONTIERS IN IMMUNOLOGY, vol. 10, 2019, pages 1296 |
SILVA, J-P. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 9, 2015, pages 5462 - 5469 |
SOOS, M.A. ET AL.: "A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity", J BIOL CHEM, vol. 267, no. 18, 1992, pages 12955 - 63, XP002477383 |
WALLE ET AL., EXPERT OPIN. BIOL. THER., vol. 7, no. 3, 2007, pages 405 - 418 |
WOODS, K.A. ET AL.: "Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene", N ENGL J MED, vol. 335, no. 18, 1996, pages 1363 - 7 |
XIONG, L. ET AL.: "Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor", PROC NATL ACAD SCI USA, vol. 89, no. 12, 1992, pages 5356 - 60, XP002423617, DOI: 10.1073/pnas.89.12.5356 |
YAMADA, T. ET AL.: "Therapeutic monoclonal antibodies", KEIO JOURNAL OF MEDICINE, vol. 60, no. 2, 2011, pages 37 - 46 |
Also Published As
Publication number | Publication date |
---|---|
CA3176119A1 (en) | 2021-12-09 |
CL2022003399A1 (es) | 2023-08-11 |
IL296519A (en) | 2022-11-01 |
JPWO2021246413A1 (ja) | 2021-12-09 |
CO2022017026A2 (es) | 2022-12-09 |
TW202210513A (zh) | 2022-03-16 |
KR20230006006A (ko) | 2023-01-10 |
AR122499A1 (es) | 2022-09-14 |
MX2022015133A (es) | 2023-01-11 |
CN115605594A (zh) | 2023-01-13 |
AU2021282629A1 (en) | 2022-12-01 |
JP2024054410A (ja) | 2024-04-16 |
BR112022022030A2 (pt) | 2023-01-17 |
EP4159860A1 (en) | 2023-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190016814A1 (en) | Activatable anti-pdl1 antibodies, and methods of use thereof | |
JP6787795B2 (ja) | 抗Axl抗体 | |
JP6787796B2 (ja) | 抗Axl抗体 | |
JP6987136B2 (ja) | 抗igf−i受容体抗体 | |
JP2011523414A (ja) | 抗fn14抗体、およびその使用 | |
US20150259419A1 (en) | Anti-MCAM Antibodies and Associated Methods of Use | |
US20210047415A1 (en) | Pd1 binding agents | |
JP2024054410A (ja) | 抗igf-1受容体ヒト化抗体 | |
JP2023011808A (ja) | 抗igf-i受容体ヒト化抗体 | |
WO2023032955A1 (ja) | 抗成長ホルモン抗体 | |
RU2785305C2 (ru) | Антитело против рецептора igf-i | |
JP2020537492A (ja) | FCγRII結合フィブロネクチンIII型ドメイン、それらのコンジュゲート、及びそれらを含む多重特異性分子 | |
EA046142B1 (ru) | Антитела к trem-1 и их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21817253 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022528850 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3176119 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022022030 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021282629 Country of ref document: AU Date of ref document: 20210601 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227042511 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022022030 Country of ref document: BR Free format text: COM BASE NA PORTARIA INPI 48/2022, APRESENTAR NOVO CONTEUDO ELETRONICO DE LISTAGEM DE SEQUENCIAS, POIS O CONTEUDO APRESENTADO NA PETICAO INICIAL NAO POSSUI TODOS OS CAMPOS OBRIGATORIOS (CAMPO 130). INCLUIR CAMPOS 140-141 EM RESPOSTA A EXIGENCIA, UMA VEZ QUE O DEPOSITANTE JA POSSUI O NUMERO DO PEDIDO NA FASE NACIONAL. |
|
ENP | Entry into the national phase |
Ref document number: 2021817253 Country of ref document: EP Effective date: 20230102 |
|
ENP | Entry into the national phase |
Ref document number: 112022022030 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221028 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522440892 Country of ref document: SA |